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RÉSUMÉ 
Le cancer du poumon a une incidence et une létalité parmi les plus hautes de tous les 
cancers diagnostiqués au Canada.  En considérant la gravité du pronostic et des 
symptômes de la maladie, l’accès au traitement dans les plus brefs de délais est 
essentiel. Malgré l’engagement du gouvernement fédéral et les gouvernements 
provinciaux de réduire les délais de temps d’attente, des balises pour les temps 
d’attente pour le traitement d’un cancer ne sont toujours pas établis.  En outre, le 
compte-rendu des indicateurs des temps d’attente n’est pas uniforme à travers les 
provinces.  Une des solutions proposées pour la réduction des temps d’attente pour 
le traitement du cancer est les équipes interdisciplinaires. J’ai complété un audit du 
programme interdisciplinaire traitant le cancer du poumon à l’Hôpital général juif 
(l’HGJ) de 2004 à 2007.  Les objectifs primaires de l’étude étaient : (1) de faire un 
audit de la performance de l’équipe interdisciplinaire à l’HGJ en ce qui concerne les 
temps d’attente pour les intervalles critiques et les sous-groupes de patients ; (2) de 
comparer les temps d’attente dans la trajectoire clinique des patients traités à l’HGJ 
avec les balises qui existent ; (3) de déterminer les facteurs associés aux délais plus 
longs dans cette population.  Un objectif secondaire de l’étude était de suggérer des 
mesures visant à réduire les temps d’attente.  Le service clinique à l’HGJ a été 
évalué selon les balises proposées par le British Thoracic Society, Cancer Care 
Ontario, et la balise pan-canadienne pour la radiothérapie.  Les patients de l’HGJ ont 
subi un délai médian de 9 jours pour l’intervalle «Ready to treat to first treatment», 
et un délai médian de 30 jours pour l’intervalle entre le premier contact avec 
l’hôpital et le premier traitement. Les patients âgés de plus de 65 ans, les patients 
avec une capacité physique diminuée, et les patients avec un stade de tumeur limité 
étaient plus à risque d’échouer les balises pour les temps d’attente.   
 
 
 
Mots-clés : temps d’attente, le cancer du poumon, le traitement du cancer, les 
équipes interdisciplinaires, qualité des soins, points de repère, évaluation de 
performance, « critical pathways »  
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ABSTRACT 
 
Lung cancer is among the most lethal and the most diagnosed cancers in Canada. 
Given the poor prognosis and symptom burden of the disease, timely access to 
treatment and quality care are essential. In spite of government commitments to 
reduce waiting times in cancer care, national clinical benchmarks for cancer care 
have yet to be established, and waiting time reporting by provinces is inconsistent. 
One of the proposed strategies for reducing waiting times in cancer care is the use of 
interdisciplinary teams. I undertook an audit of the interdisciplinary pulmonary 
oncology program at the Jewish General Hospital from 2004 to 2007. The primary 
objectives of this study were: (1) to audit the performance of the interdisciplinary 
pulmonary oncology service at the Jewish General Hospital with respect to waiting 
times for key intervals and subgroups of patients; (2) to compare waiting times in the 
clinical trajectory of lung cancer patients seen at the Jewish General Hospital with 
existing waiting time guidelines; (3) to determine those factors associated with 
longer waiting times in this population. A secondary objective was to suggest 
measures to be considered in order to reduce waiting times.  The JGH’s lung cancer 
service was compared against benchmarks developed by the British Thoracic 
Society, Cancer Care Ontario, and the pan-Canadian waiting time benchmarks for 
radiation oncology. Patients waited a median of 9 days from the time they were 
ready to treat until their first treatment, and a median of 30 days from their first 
contact with the pulmonary service until their first treatment. Patients over age 65, 
those with early-stage disease and those with good performance status were less 
likely to meet the recommended guidelines. 
 
 
  
Key words: waiting times, lung cancer, cancer treatment, interdisciplinary teams, 
quality of care, guidelines, performance evaluation, critical pathways 
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INTRODUCTION           
  Lung cancer is among the most lethal and the most diagnosed cancers in 
Canada (Canadian Cancer Society, 2007).  Depending on the stage and severity of 
symptoms, treatment for lung cancer may involve surgery, radiation therapy, or 
chemotherapy, or a combination of these modalities.  Consequently, diagnosing and 
treating lung cancer involves a variety of specialists and requires close monitoring 
and coordination (Riedel, Wang, McCormack, Toloza, Montana et al., 2006). Given 
the poor prognosis and symptom burden of the disease, timely access to treatment 
and quality care are essential.  
Managing the care and treatment of lung cancer patients requires a 
comprehensive strategy that ensures early-stage patients are given the best chance of 
survival, and late-stage patients are given symptom relief with minimal delay.  
Managing waiting times is therefore an essential element of quality care in lung 
cancer.  
 
DEFINITION OF THE PROBLEM & OBJECTIVES    
Waiting times in all areas of the Canadian health care system have been the 
subject of public pressure and scrutiny for several years (Canadian Breast Cancer 
Network, 2008). Waiting time benchmarks for cancer care are among the priority 
areas targeted for development by the federal and provincial governments as part of 
the Ten-Year Plan to Strengthen Health Care announced in 2004 (Sullivan, 2006a; 
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Winget et al., 2007)1. In spite of government commitments to reduce waiting times 
in cancer care, there remains a lamentable shortage of research, reporting, and 
collaboration (Sullivan, 2006a; Winget et al., 2007). National clinical benchmarks 
for cancer care have yet to be established, and waiting time reporting by provinces is 
inconsistent and un-standardized (Canadian Institute for Health Information, 2006; 
Canadian Breast Cancer Network, 2008).   
Furthermore, relatively little is known about waiting times for the treatment 
of lung cancer in Canada, particularly among patients with advanced stages of 
disease who represent the majority of cases. Although waiting time reductions are 
being pursued across all tumor types, the impact of these efforts in the lung cancer 
population will be especially important given the rapid progression of the disease 
and the role of timely treatment on symptom palliation and tumor control (Billing & 
Wells, 1996; O'Rourke & Edwards, 2000; Bozcuk & Martin, 2001; Jensen, Mainz, 
& Overgaard, 2002; Koyi, Hillerdal, & Brandén, 2002b; Moody, Muers, & Forman, 
2004; Myrdal et al., 2004). 
One of the proposed strategies for reducing waiting times in cancer care is 
the use of interdisciplinary teams. A recent meta-analysis revealed that there is clear 
evidence suggesting that interdisciplinary team improves practice patterns and 
decision-making in the management of lung cancer patients (Coory, Gkolia, Yang, 
Bowman, & Fong, 2008).  Although the benefits of interdisciplinary teams to the 
management of lung cancer may seem intuitive, there is a shortage of evidence to 
corroborate this stance (Coory et al., 2008). Interdisciplinary teams have not been 
                                                 
1
 The other four priority areas targeted by the provinces in 2004 for waiting time reduction were 
cardiac care, joint replacement, cataract surgery, and diagnostic imaging (Canadian 
Intergovernmental Conference Secretariat, 2004). 
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widely or systematically adopted in Canada, nor has their performance been 
evaluated in relation to waiting times.  
The Jewish General Hospital in Montreal has been operating an 
interdisciplinary lung cancer program for over ten years. The primary objectives of 
this study were: (1) to audit the performance of the interdisciplinary pulmonary 
oncology service at the Jewish General Hospital with respect to waiting times for 
key intervals and subgroups of patients; (2) to compare these waiting times with 
existing waiting time guidelines; (3) to determine those factors associated with 
longer waiting times in this population. A secondary objective was to suggest 
measures to be considered in order to reduce waiting times.  
The JGH’s lung cancer service was compared against benchmarks developed 
by the British Thoracic Society (BTS) (1998), Cancer Care Ontario (CCO) (2006), 
and the pan-Canadian waiting time benchmarks for radiation oncology (Ontario 
Ministry of Health and Long-Term Care, 2005).  These particular sources were used 
in order to assess the performance of the JGH’s service in a variety of contexts:  
• Assessing against the lung cancer-specific BTS guidelines will situate 
the JGH within the treatment of lung cancer in the international 
community.  
• Assessing against the Cancer Care Ontario guidelines will allow the 
comparison of the JGH’s service against the only generalized, 
comprehensive cancer benchmarks that have been set in Canada.   
• Assessing against the pan-Canadian benchmarks for radiation 
oncology will allow a comparison of how well the JGH service fares 
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against the only Canada-wide waiting time goal for cancer care. 
 
WHY EXAMINE WAITING TIMES IN LUNG CANCER?   
Waiting times in cancer care have been described as the “canary in the mine” 
of Canada’s health care system (Sullivan, 2006a).  They reflect the quality and 
continuity of clinical services and the capacity of the system to manage demands. 
Examining waiting times is particularly critical for lung cancer, given the aggressive 
nature of the disease and the devastating symptoms that many patients experience.  
The recent attention to waiting times by the federal and provincial governments and 
the nascent interest in establishing benchmarks for care underline the importance of 
assessing the current state of affairs and identifying areas that require special 
attention. 
Waiting times can be assessed along a patient’s entire course of illness, from 
detection of first symptoms to completion of treatment and discharge from hospital 
(Moody et al., 2004).  Assessing the waiting time at each phase of a patient’s course 
of illness will focus on the quality of different facets of the health care system.  For 
instance, the waiting time between detection of first symptoms and first visit to a 
generalist includes elements such as effectiveness of health promotion and access to 
a family physician, while also reflecting individual characteristics such as patient 
education, perceptions of the health care system, and fears (Moody et al., 2004).  
Examining waiting times from first specialist visit to treatment reflects the quality of 
clinical services in a hospital setting and the capacity of the centre to handle 
demands (Sullivan, 2006a).  While this phase represents only a fraction of the 
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waiting a patient will do over the course of his or her illness, it is a critical period in 
the management of the illness. Accordingly, this phase has been the subject of 
several studies and standards related to waiting times. 
Assessing waiting times in lung cancer at a single centre is clearly not 
representative of the system across Canada, across Québec, or even in the city of 
Montréal. However, it does illustrate a microcosm of the provision of cancer 
services in an interdisciplinary context. It presents a more detailed view of the 
strengths and weaknesses of clinical services and identifies areas of improvement. 
Moreover, the results of the analysis of the strengths and weaknesses of clinical 
services and the comparison of clinical performance against established guidelines 
may not be limited to the Jewish General Hospital. Lessons learned may be useful to 
other hospitals within the city, the province, or within Canada. Furthermore, a 
comparative analysis of the timeliness of care is a contribution to the improvement 
of the quality of patient care, and is a useful tool for policy makers and health-care 
providers (Winget et al., 2007). 
The number of Canadians diagnosed with cancer has been growing steadily, 
and is likely to continue to do so for the foreseeable future (Canadian Cancer 
Society, 2007).  Having a sense of the current state of affairs and direction for the 
future is critical to ensuring that all patients, regardless of where they are in Canada, 
are receiving the treatment that they require within a reasonable delay.   
 
CONCEPTUAL FRAMEWORK          
 The conceptual framework serving as the basis of the analysis is the critical 
pathways approach. Critical pathways are well-established in the medical 
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community as a management tool to define the sequence and timing of key actions 
in a patient’s care plan (Pearson, Goulartfisher, & Lee, 1995).  Critical pathways are 
concerned with improving the quality of care and reducing unnecessary variations in 
patient treatment.  Although similar to clinical practice guidelines, critical pathways 
differ in that they are primarily process-oriented and systematic, and deviations from 
the process may therefore highlight inefficiencies in patient care. Clinical practice 
guidelines, on the other hand, are consensus statements that are developed to assist 
clinicians in making decisions regarding patient care (Every, Hochman, Becker, 
Kopecky, & Cannon, 2000).  Although clinical practice guidelines are often used in 
conjunction with critical pathways, many of the components of critical pathways 
have not been tested in clinical trials and are therefore not covered in guidelines 
(Every et al., 2000).    
The classic interpretation of a critical pathway is the sequence in a process 
that takes the longest time to complete, thus contributing the most to the overall time 
(Pearson et al., 1995).  They originated from management processes in industry used 
to identify variations and rate-limiting steps that hampered production. Critical 
pathways were adapted for use in the medical community beginning in the 1980s, 
primarily as a nursing tool (Pearson et al., 1995; Every et al., 2000). As Pearson and 
colleagues (1995) outline, the goals of critical pathways in health care differ from 
the industrial model.  Table 1 summarizes the main objectives of critical pathways 
in health care.   
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Table 1: Goals of critical pathways in health care 
1. Selecting a "best practice" when practice styles vary unnecessarily. 
 
2. Defining standards for the expected duration of hospital stay and for the use of 
tests and treatments. 
 
3. Examining the interrelations among the different steps in the care process to find 
ways to coordinate or decrease the time spent in the rate-limiting steps. 
 
4. Giving all hospital staff a common "game plan" from which to view and 
understand their various roles in the overall care process. 
 
5. Providing a framework for collecting data on the care process so that providers 
can learn how often and why patients do not follow an expected course during their 
hospitalization. 
 
6. Decreasing nursing and physician documentation burdens. 
 
7. Improving patient satisfaction with care by educating patients and their families 
about the plan of care and involving them more fully in its implementation. 
Adapted from Pearson et al.(1995) and Every et al. (2000) 
 
A critical pathways approach is a particularly appropriate method for 
examining waiting times for treatment. As described by Every and colleagues 
(2000), one of the functions of a critical pathway is its role as a series of time-
associated actions. The actions examined in the present study are points along a lung 
cancer patient’s clinical trajectory, including first consultation with a specialist, 
diagnosis, staging, and initiation of treatment. These actions are divided into 
intervals that contribute to the overall waiting time from first consultation to first 
treatment. The critical pathways approach is additionally suited to this analysis 
because of its emphasis on multidisciplinary involvement and on the use of 
benchmarks. Since critical pathway processes are not often the subject of rigorous 
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scientific study, benchmarks and best practices are often used to measure success 
(Every et al., 2000).  
There are many factors that may influence a patient’s waiting time at any 
interval along their clinical trajectory. This study will examine some well-
documented factors, namely the stage of disease and urgency of treatment, the 
complexity of the diagnostic process, the complexity of the treatment plan, 
scheduling and referrals, and the patient’s overall fitness for treatment (Moody et al., 
2004; Salomaa, Sallinen, Hiekkanen, & Liippo, 2005; Canadian Institute for Health 
Information, 2006; Sullivan, 2006a; Devbhandari, Soon et al., 2007).  These factors 
reflect larger organizational issues such as the capacity of the treatment facility to 
handle demands, both in terms of human and physical resources. 
In the context of this study, the critical pathways framework will be used 
primarily as a tool to identify rate-limiting steps in the clinical trajectory of lung 
cancer patients. Framing waiting times in terms of a critical pathway is an 
acknowledgement of the importance of decreasing unnecessary variation in patients’ 
treatment experiences, and it assists in focusing attention on the quality of care. A 
caveat to this is the wide variation in patient needs and experiences, which cannot 
and should not be captured in a critical pathway. Achieving a balance between 
harmonizing patient care and respecting individual needs and preferences is the 
primary challenge with critical pathways (Pearson et al., 1995; Every et al., 2000).   
In the context of this study, the concept of critical pathways will be the basis 
of the analysis.  Intervals in the clinical trajectory of lung cancer patients will be 
broken down into time-associated actions, much in the way a critical pathway would 
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be organized, in order to highlight inefficiencies. The entire clinical trajectory of a 
lung cancer patient in the hospital setting, from first consultation with a specialist to 
initiation of treatment, will be divided into segments representing the important 
stages in the care of the patient. The segment in the trajectory that takes the longest 
amount of time to complete is the critical pathway. The identification of the critical 
pathway will lead to an assessment of how this rate-limiting step can be altered in 
order to reduce the its timeline, and in turn, reduce the overall timeline of the clinical 
trajectory. 
 
PLAN              
 This first section has outlined in brief the issue, objectives and justification 
of this study, as well as defining a conceptual framework for the methodology and 
analysis of the results. The following section will provide context and further detail 
for the topics of lung cancer, waiting times, and multidisciplinary teams in cancer 
care.  Section 3 will describe in detail the methodology of the study, including the 
sample, data collection, time interval calculation, and statistical analysis.  Following 
the methodology section is an article entitled Waiting times in the clinical trajectory 
of patients with lung cancer, which forms the main analytic component of this text.  
The article is complemented by an analysis section that discusses the contribution of 
this research to current knowledge, and reflects on its limitations and areas of further 
study. Annex 1 includes diagrams of detailed clinical trajectories and Annex 2 
includes further results from the waiting time analysis. 
  
 
 
SECTION 2: 
 
LUNG CANCER, 
WAITING TIMES, 
AND 
INTERDISCIPLINARY 
TEAMS 
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THE BURDEN OF LUNG CANCER IN CANADA    
Lung cancer is the leading cause of cancer death among Canadian men and 
women. It has held this unenviable status since the early 1990s, outpacing the 
mortality rates of breast, prostate, and colorectal cancers. In 2007, an estimated 
23,300 cases were diagnosed and 19,900 deaths resulted from lung cancer (Canadian 
Cancer Society, 2007).   
Its five-year relative survival is among the lowest of all cancers, ranking with 
pancreatic, esophageal and liver cancers in terms of lethality (Canadian Cancer 
Society, 2007). Aside from being one of the deadliest cancers, lung cancer is largely 
preventable. Approximately 90% of patients diagnosed with lung cancer are smokers 
or former smokers. The remainder may have had occupational exposure to 
carcinogenic agents, although there is some evidence to suggest that genetics play a 
role in the development of lung cancer in never-smokers (Toh et al., 2006).   
Given that the link between tobacco smoke and lung cancer is well established, 
most public health efforts to control lung cancer have been focused on smoking 
cessation and prevention. As a result of prevention activities, smoking rates among 
Canadian youth have dropped by more than half in the last 40 years (Health Canada, 
2004). Further evidence of this success can be seen in the plateau of lung cancer 
incidence rates among men and the recent slowdown of lung cancer incidence rates 
among women (Canadian Cancer Society, 2007). Figure 1 shows the trend in 
incidence rates for selected cancers among men and women since 1978. 
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Figure 1: Age-standardized2 incidence rates (ASIR) for selected cancers, 1978-
2007 
 
       
 
            
 
  From Canadian Cancer Statistics 2007 (Canadian Cancer Society, 2007) 
 
Today’s lung cancer incidence rates reflect the smoking habits of individuals 
twenty to thirty years prior. The incidence of lung cancer began to decline in men in 
the late 1980s, which reflected a drop in male smoking rates in the mid-1960s.  
                                                 
2
 Rates are standardized to the age distribution of the Canadian population in 1991. 
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Incidence rates among women are currently thought to be leveling off, which 
reflects the decline in female smoking in the mid-1980s (Canadian Cancer Society, 
2007).   
In spite of the continuing progress being made in smoking prevention and 
cessation, and the correlative reductions in lung cancer incidence and mortality, it 
remains among the most diagnosed cancers in Canada (Canadian Cancer Society, 
2007). Consequently, the management of lung cancer remains a major public health 
challenge. For those individuals who are diagnosed with the disease, high-quality 
and timely care is essential to increasing survival and improving their quality of life.   
 
LUNG CANCER: SYMPTOMS AND DETECTION    
In spite of ongoing research efforts to identify one, a reliable and cost-effective 
screening tool for lung cancer does not yet exist (Welch et al., 2007).  Without a 
screening program, patients and general practitioners are charged with identifying 
symptoms and abnormalities that may indicate a malignancy. However, the 
symptoms of lung cancer are not unique to the disease and thus may be challenging 
to identify. Patients who develop lung cancer often have comorbidities with similar 
symptom profiles, such as chronic obstructive pulmonary disease (COPD), 
emphysema, and chronic bronchitis (Koyi et al., 2002b). The most common lung 
cancer symptoms include persistent cough, shortness of breath, unexplained weight 
loss, night sweats, fatigue, loss of appetite, and hemoptysis (National Cancer 
Institute, 2007a, 2007b). These symptoms are often undetectable until the cancer is 
at an advanced stage (Moody et al., 2004). As a result, the majority (approximately 
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80%) of lung cancer is diagnosed at a later stage of disease, for which curative 
treatment is not available (Koyi et al., 2002b; Birring & Peake, 2005). Curative 
surgical resection provides the most favourable five-year survival rates, but is only 
feasible in the earliest stages of lung cancer (Jensen et al., 2002; Myrdal et al., 2004; 
Salomaa et al., 2005).  
Lung cancer is classified into two types: small-cell and non-small cell. These 
designations refer to the distinctive histological features of the cancers. Clinical and 
radiological features of small cell and non-small cell also differ, as do treatment 
options.  However, diagnosis and staging of either small cell or non-small cell lung 
cancer is achieved using the same procedures: biopsy, chest x-ray, CT scan and PET 
scan (National Cancer Institute, 2007a, 2007b). Histological confirmation is required 
for a definitive diagnosis of lung cancer. 
 
NON-SMALL CELL LUNG CANCER: STAGING AND 
TREATMENT 
Non-small cell lung cancer (NSCLC) can be further divided into subtypes, 
including adenocarcinoma, squamous carcinoma, and large cell carcinoma (National 
Cancer Institute, 2007a). Upon diagnosis of NSCLC, patients are staged according to 
TNM criteria  (Tumor, Nodes, Metastasis) as either Stage I, II, III or IV according to 
the severity of their disease (Mountain, 1997).  Table 2 and Figure 2 outline the 
TNM staging criteria and explain the salient features of the T, N and M descriptors.  
The TNM status of each patient determines their stage of disease, which ranges from 
IA to IV (least severe to most severe).  Accurate staging of patients is essential to 
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determining their treatment options and overall prognosis.  Based on their stage, 
patients can then be assigned to one of three categories: early stage, locally 
advanced, and advanced metastatic disease (National Cancer Institute, 2007a).   
 
Table 2: Staging criteria based on T-N-M classification 
 
Stage Primary Tumor  
(T) 
Regional Lymph 
Nodes (N) 
Distant Metastasis  
(M) 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T1 N1 M0 
IIB T2 
T3 
N1 
N0 
M0 
M0 
IIIA T3 
T1, T2, T3 
N1 
N2 
M0 
M0 
IIIB T4 
Any T 
N0, N1, N2 
N3 
M0 
M0 
IV Any T Any N M1 
Adapted from Mountain(1997) 
 
Figure 2: Key TNM descriptors 
Primary tumor (T) 
T1: Tumor ≤3 cm in greatest dimension, surrounded by lung or visceral pleura, without evidence of 
invasion into the main bronchus 
T2: Tumor with any of the following features of size or extent: 
>3 cm in greatest dimension 
Involves main bronchus, ≥2 cm distal to the carina 
Invades the visceral pleura 
T3: Tumor of any size that directly invades any of the following: chest wall, diaphragm, mediastinal 
pleura, parietal pericardium; or tumor in the main bronchus ≤2 cm distal to the carina, but without 
involvementof the carina; or associated atelectasis or obstructive pneumonitis of the entire lung 
T4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, 
esophagus, vertebral body, carina; or tumor with a malignant pleural or pericardial effusion, or with 
satellite tumor nodule(s) within the ipsilateral primary-tumor lobe of the lung 
 
Regional lymph nodes (N) 
N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary 
nodes involved by direct extension of the primary tumor 
N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph node(s) 
 
Distant metastasis (M) 
M0: No distant metastasis 
M1: Distant metastasis present 
Adapted from Mountain(1997) 
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Early stage patients are those with operable disease, confined to Stages I-II, 
and in select cases, IIIA. These patients can be treated with surgery, or surgery 
combined with adjuvant chemotherapy where indicated.  Early stage patients have 
the most favourable prognosis.  Patients with locally advanced or regionally 
advanced disease (Stages IIIA and IIIB) can be treated, in some cases, with surgery 
followed by chemotherapy or radiation therapy, or with combined chemotherapy-
radiotherapy. Patients with distant metastases (Stage IV) have the most ominous 
prognosis, and depending on their symptoms and other comorbidities, may be 
offered chemotherapy or radiotherapy to palliate symptoms. Those patients with a 
poor performance status (PS), deemed not physically strong enough to tolerate 
treatment, are monitored and offered supportive care (National Cancer Institute, 
2007a). 
 
SMALL CELL LUNG CANCER: STAGING AND TREATMENT 
 Small-cell lung cancer (SCLC) is more aggressive than NSCLC: without 
treatment, median survival for SCLC is only two to four months from the time of 
diagnosis (National Cancer Institute, 2007b). However, SCLC responds more readily 
to chemotherapy and radiation therapy than NSCLC.  The staging of SCLC does not 
follow the TNM criteria; rather, SCLC is bisected into limited stage disease and 
extensive stage disease (National Cancer Institute, 2007b). 
 Patients with limited stage disease have a tumor that is confined to one lung, 
the mediastinum, or regional lymph nodes.  Median survival for these patients is 16 
to 24 months with treatment (National Cancer Institute, 2007b).  Combination 
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chemotherapy (two or more drugs) is the treatment of choice for limited stage 
SCLC.  Patients often receive concurrent high-dose radiation to the chest, and may 
also receive prophylactic cranial irradiation (PCI) if they achieve a complete 
response to chemotherapy (National Cancer Institute, 2007b). 
The majority (70%) of patients with SCLC have extensive stage disease at 
the time of diagnosis. These patients have distant metastases, and thus a shorter 
prognosis. Median survival for patients with extensive stage disease is 6 to 12 
months with treatment, and long term disease-free survival is rare (National Cancer 
Institute, 2007b). Current treatment options for extensive stage disease include 
combination chemotherapy, and where indicated, palliative radiation therapy to 
distant metastases, particularly brain and bone (National Cancer Institute, 2007b).    
 
FACTORS AFFECTING PROGNOSIS       
While survival has improved for many solid tumours in the past twenty 
years, the prognosis for lung cancer has remained stagnant (Moody et al., 2004; 
Birring & Peake, 2005). This is due mainly to the key prognostic indicators for lung 
cancer, which include stage, performance status, histological type, comorbidities, 
and the time between first symptom and first treatment (Moody et al., 2004). This 
latter factor is of particular interest because it can be improved, whereas most of the 
former factors cannot be modified. Timely access to services may potentially 
facilitate the diagnosis of lung cancer at an earlier stage of disease, providing more 
options for treatment and a more favourable clinical outcome (Moody et al., 2004).   
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A number of factors influence the time from first symptoms to the first 
treatment. Moody (2004) presents four pertinent intervals: between first malignant 
change and first symptom; between first symptom and presentation; between first 
presentation and confirmation of diagnosis; and between diagnosis and 
staging/treatment. With respect to treatment delays, the two former intervals can be 
divided into patient delays and the latter two intervals into hospital delays.  It is the 
latter two intervals, the hospital delay, that are the subject of this study, since these 
two intervals relate directly to the quality of care in a hospital setting and not to the 
patient’s own delay in seeking treatment (Myrdal et al., 2004).  
 
WAITING TIMES         
Waiting times have become a focus of attention and investment because they 
are a reflection of the status of health care delivery in Canada, which includes 
aspects such as long-term planning, accessibility, and capacity (Sullivan, 2006a). 
Waiting times are influenced by a number of factors, including the burden of 
disease, the availability of specialists, availability of space and other resources, and 
urgency of treatment (Canadian Institute for Health Information, 2006). Waiting 
times for treatment are primarily an indication of the quality and continuity of health 
care services (Sullivan, 2006b). In Québec, the Programme québécois de lutte contre 
le cancer (PQLC) lists waiting times as the first of the key performance indicators of 
a cancer program (1997):  
Indicateurs de performance 
 Délais entre le moment du diagnostic et le début du 
traitement. 
 Incidence des complications thérapeutiques: 
postopératoires, postradiothérapie et 
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postchimiothérapie. 
 Survie sans évidence de récidive. 
 Survie globale. 
 Taux de mortalité.  
Waiting times are more than simply a performance indicator.  Although 
evidence linking survival to waiting times is limited, research indicates that waiting 
times can impact patient health (Canadian Institute for Health Information, 2006). 
With respect to cancer care, lengthy waiting times are correlated with psychosocial 
morbidity for many tumour types (Simunovic et al., 2001; Ristvedt & Trinkaus, 
2005a; Lyckholm, 2006), and there is some evidence to suggest that a patient’s 
anxiety is reduced once he begins treatment (Montazeri, Milroy, Hole, McEwen, & 
Gillis, 1998).   
As outlined in the following sections, however, the literature is contradictory 
regarding the impact of waiting times on the progression of disease and the effect of 
delays on prognosis.  Particularly in the lung cancer literature, there is no definitive 
evidence that longer waiting times are linked to shorter survival.  In fact, some 
studies have shown that patients with more advanced disease, and therefore a more 
limited prognosis, have shorter waiting times than their early-stage counterparts 
(Salomaa et al., 2005; Gould, Ghaus, Olsson, & Schultz, 2008).  This is thought to 
be related to the increased symptom burden that accompanies an advanced disease 
stage.  If there is no firm link between longer waiting times and poorer health 
outcomes, why is there an impetus to examine, and ultimately shorten, waiting 
times? 
One important factor is access to health care.  Canada’s health care spending, 
now at 10.7% of GDP, is at a record high (Canadian Institute for Health Information, 
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2008).  In spite of this unprecedented spending, there remain limits to the capacity 
and access to the public health care system for many taxpayers. This puts the onus 
on politicians and policymakers to reduce lengthy waiting times and improve access 
for all Canadians.  However, before 2004, there was no national waiting times 
reporting mechanism, which made the measurement and reduction of waiting times 
impossible (Canadian Institute for Health Information, 2006). Efforts began in 2004 
to determine the waiting times for various key procedures as a first step towards 
reducing them. 
In 2004, the First Ministers of Canada agreed to a ten-year plan to strengthen 
health care (Canadian Intergovernmental Conference Secretariat, 2004).  
Specifically, they committed to improving access to care and reducing waiting times 
in several key areas, including joint replacement, cardiac care, sight restoration, 
diagnostic imaging, and cancer care.  In order to meet this commitment, the First 
Ministers agreed to collect information from provinces on existing waiting times in 
order to create “comparable indicators of access to health care”, and also pledged to 
establish “evidence-based benchmarks for medically acceptable wait times” 
(Canadian Intergovernmental Conference Secretariat, 2004). The provinces 
committed to establishing and reporting on waiting time benchmarks for cancer 
treatment including surgery, radiation therapy and systemic therapy by the end of 
2005 (Canadian Institute for Health Information, 2006). The original deadline passed 
with only modest progress, in the form of national radiation therapy benchmarks 
(Canadian Intergovernmental Conference Secretariat, 2004), and piecemeal 
22 
 
reporting of waiting time indicators (Canadian Institute for Health Information, 
2006).  
In terms of cancer care, the First Ministers’ promise to establish evidence-
based benchmarks has proven difficult to fulfil. Medically acceptable waiting times 
refer to the maximum interval within which a patient is treated without an adverse 
effect on his health (Wait Time Alliance for Timely Access to Health Care, 2005).  
However, there is a dearth of reliable evidence on the impact of treatment delay on 
survival in all types of cancer, given the ethical impossibility of running a 
randomized controlled trial to assess its impact. As a result, the best available 
evidence is from retrospective studies, which do not permit the control of certain key 
factors such as stage at diagnosis (Liberman, Liberman, Sampalis, & Mulder, 2006).  
Furthermore, cancer is not a single entity.  Even within a particular tumor site, 
cancers grow differently within individuals; the risk of treatment delay is not 
uniform among all patients or for all cancers (Canadian Institute for Health 
Information, 2006). Determining evidence-based benchmarks for waiting times in 
cancer care is therefore extremely challenging.  
Consequently, the evidence on waiting times in cancer care in Canada is 
limited, both in assessing the wait at various institutions and in determining its 
impact on survival. Most provinces have begun to publish their own waiting times 
data; however, since there is no consensus on the intervals being examined, most 
provinces start measurements at different points along the care trajectory (Canadian 
Institute for Health Information, 2007; Winget et al., 2007). This makes inter-
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provincial comparisons challenging in addition to complicating the comparison of 
individual centres to provincial norms.  
 
Guidelines 
In spite of the challenges inherent in establishing waiting time guidelines, 
several organizations have proposed recommendations for waiting times in the 
clinical trajectory of cancer patients. The British Thoracic Society (1998) and the 
Swedish Lung Cancer Study Group (Myrdal et al., 2004) have proposed specific 
recommendations for lung cancer, whereas Cancer Care Ontario (2006) and the Wait 
Time Alliance (2007) have made general recommendations for all cancer types.  
Furthermore, the First Ministers have agreed to a pan-Canadian radiation oncology 
benchmark (Ontario Ministry of Health and Long-Term Care, 2005; Canadian 
Institute for Health Information, 2006; Wait Time Alliance for Timely Access to 
Health Care, 2007).  In all cases, these recommendations have been made based on 
the expertise of practitioners and their clinical judgment, rather than on evidence 
from clinical studies. The Canadian recommendations are clinical performance 
benchmarks rather than medically acceptable or ideal waiting times (Cancer Care 
Ontario, 2006; Wait Time Alliance for Timely Access to Health Care, 2007). Tables 
3-7 outline the waiting time recommendations from the various organizations.   
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Table 3: Recommendations of the British Thoracic Society 
Interval 
 
Time 
(days) 
Time to Diagnosis (TTD) 14 
 
Time to Treatment (TTT)Ω 
Surgery 
Chemotherapy 
Radiotherapy 
 
28 
7 
14/28φ 
Ω: from date of decision to treat to treatment 
φ
: 14 days for palliative treatment and 28 days for radical treatment where complex planning is 
required. 
 
 The recommendations of the British Thoracic Society were published in 
1998 in order to provide guidance to respiratory physicians in the management of 
lung cancer.   They were produced in light of several national reports on the status of 
cancer care in the United Kingdom and represented an opportunity for the BTS to 
contribute to improved patient care.  The recommendations are based on “considered 
clinical opinion” (British Thoracic Society, 1998) and, where possible, published 
scientific evidence.  The guidelines include not only recommendations on waiting 
times, but provide a comprehensive picture of lung cancer management standards, 
from first presentation through death and bereavement (British Thoracic Society, 
1998).  The recommendations of the BTS with respect to waiting times have been 
cited in a number of international studies, which will be discussed below. 
Table 4: Recommendations of the Swedish Lung Cancer Study Group 
Interval 
 
Time 
(days) 
TTD 28 
TTT 
Surgery 
Chemotherapy 
Radiotherapy 
 
14 
14 
14 
80% of patients are recommended to be seen within this time interval 
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 The Swedish Lung Cancer Study Group made its waiting time 
recommendations in a study published by Myrdal and colleagues (2004), reporting 
on the effect of delays on the prognosis of patients with NSCLC.  Its 
recommendations relate only to the two intervals outlined above.  Their 
recommendations have been assessed in several studies, as outlined below. 
 
Table 5: Recommendations of Cancer Care Ontario 
Interval 
 
Time 
(days) 
Referral to Consult 
Surgery 
Chemotherapy 
Radiotherapy 
 
 
-- 
7(II)/14(III) 
7(II)/14(III) 
Consult to Decision to Treat 
(DTT)  
Surgery 
Chemotherapy 
Radiotherapy 
 
 
14 
-- 
-- 
Ready to Treat (RTT) to 
treatment: 
Surgery 
Chemotherapy 
Radiotherapy 
 
 
(II)14/(III)28 
(II)7/(III)14 
(II)7/(III)14 
 
Cancer Care Ontario published its target waiting time recommendations in 
2006.  The recommendations cover all cancer types and are prioritized based on the 
judgment of the physician. Priority is determined by the urgency of the case and the 
aggressiveness of the tumor (Cancer Care Ontario, 2006). The notations (II) and (III) 
refer to priority levels, with level II being more urgent than level III. Cancer Care 
Ontario recommends that ninety percent of patients be seen within these time 
intervals.   
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The target waiting times were created to monitor the relationship between 
demand and capacity to provide services, and as such were not intended to represent 
medically acceptable waiting times. Multidisciplinary committees were used to 
determine target waiting times for each of the priority categories and each of the 
treatment modalities.  The Decision to Treat (DTT) and Ready to Treat (RTT) dates 
are usually the same, unless there is a planned wait.  A planned wait is any wait that 
is not related to a system access issue and can include patient waits such as travel or 
personal business, or physician waits such as a delay for a medical reason (Cancer 
Care Ontario, 2006).  
 
Table 6: Benchmarks of the Wait Time Alliance (WTA) 
 
Interval 
 
Time 
(days) 
Initial referral to consultation to 
radiation oncology 
 
14 
 
Decision to treat to initiation of 
radiation treatment 
14 
 
  
The Wait Time Alliance for Timely Access to Health Care is comprised of 
several national medical specialty societies including the Canadian Association of 
Nuclear Medicine, the Canadian Association of Radiation Oncologists, and the 
Canadian Medical Association, among many others. Since 2005, the Wait Time 
Alliance has monitored and reported on progress toward establishing waiting time 
benchmarks in the five priority areas defined by the First Ministers. They have 
recommended waiting time benchmarks not only for the five priority areas, but also 
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for other specialty areas and procedures (Wait Time Alliance for Timely Access to 
Health Care, 2005, 2007).   The only benchmark set for cancer care, however, is for 
radiation oncology.  There is no indication of progress toward other benchmarks for 
cancer treatment.    
 
Table 7: pan-Canadian benchmarks for Radiation Oncology 
 
Interval 
 
Time 
(days) 
Ready to treat to initiation of 
treatment 
28 
 
 
 In 2005, the First Ministers of Canada agreed to a common goal of treating 
radiation patients within 4 weeks of being ready to treat (Ontario Ministry of Health 
and Long-Term Care, 2005).  This is the only common benchmark that has been 
established for cancer care to date; however, progress towards this benchmark is 
being reported by nearly all provinces and territories (Canadian Institute for Health 
Information, 2007).  
 
Canadian evidence on waiting times in lung cancer 
Canadian studies assessing waiting times in lung cancer have focused 
predominantly on early-stage surgical patients and radiotherapy treatment. Johnston 
and colleagues (2004) examined the waiting time for radiotherapy in a mixed cancer 
population in Nova Scotia between 1992 and 2000.  They found that the median 
time from cancer diagnosis to radiation treatment for lung cancer patients was 6 
weeks.  They found no association between waiting time and age in the lung 
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population, although they did find an association between shorter waiting time and 
more advanced disease (Johnston et al., 2004).  The authors explained this finding 
by noting that patients with lung cancer generally require palliative radiation as they 
are usually in a more advanced disease stage.  Palliative radiation is less complex 
and requires less planning than curative radiation, as the objective is immediate 
relief of pain.  The authors also noted that the majority of lung cancer patients in the 
study were inpatients at the time of referral and therefore were processed more 
rapidly than their ambulatory counterparts (Johnston et al., 2004). 
Liberman and colleagues (2006) examined patients who had undergone 
surgical resection for NSCLC between 1993 and 2002 at the Montreal General 
Hospital.  Case records were linked to RAMQ data to obtain dates of physician 
visits.  The authors found that the mean time between first contact with a thoracic 
surgeon and surgery was 104 days, which they characterized as “excessively long” 
(Liberman et al., 2006).  They attributed this partly to the delays in access to 
diagnostic tests such as CT scans and bronchoscopy, and to the delays between the 
multiple visits patients are required to make in order to complete all preoperative 
tests.  The authors suggest that a multidisciplinary lung clinic allowing patients to 
access all of the required specialists at once and allow more rapid access to 
diagnostic services would partially alleviate the long wait (Liberman et al., 2006).   
Berthelet and colleagues (2006) examined the waiting times for treatment of 
patients with limited stage SCLC between 1991 and 1999 at a BC Cancer Agency 
centre.  They found that the median time from abnormal chest x-ray to initiation of 
chemotherapy was 47 days, and the median time from diagnosis to initiation of 
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chemotherapy was 27 days.  They compared the time intervals to clinical outcomes 
and found no statistical correlations between treatment intervals and clinical 
outcomes. Although they did not comment on the association between prompt 
treatment intervals and the nature of the treatment environment, the authors did 
mention that the cohort was treated by “a consistent group of oncologists working in 
a site-specific multidisciplinary setting” (Berthelet et al., 2006). 
 
International evidence on waiting times in lung cancer 
The international literature on lung cancer waiting times has focused 
primarily on the effect of delays on survival, with particular attention paid to early-
stage resectable lung cancer. In a meta-analysis, Jensen and colleagues (2002) 
examined the evidence on the rate of tumour growth in lung cancer and its relation 
to treatment delay. They concluded that the evidence related to the prognostic 
impact of delays is contradictory. One study reported a rapid increase in tumour 
doubling time, which rendered certain patients ineligible for curative radiotherapy. 
This is consistent with other studies that have demonstrated that tumour growth is 
exponential. However, other studies reported that delays had no effect on lung 
cancer stage (Jensen et al., 2002). 
Other studies (Billing & Wells, 1996; Bozcuk & Martin, 2001; Koyi et al., 
2002b; Myrdal et al., 2004; Salomaa et al., 2005; Rolke, Bakke, & Gallefoss, 2007) 
originating from Sweden, Finland and the United Kingdom have concluded that 
delays in various points along the care trajectory (including patient-induced and 
hospital-induced delays) do not negatively impact survival.  In fact, two studies 
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found that patients with a shorter delay have a poorer prognosis (Myrdal et al., 2004; 
Salomaa et al., 2005). The researchers concluded that patients with more severe 
symptoms and more advanced disease at presentation are treated more quickly, and 
therefore have a shorter delay.  
Although the authors did not find evidence indicating a link between 
treatment delay and shorter survival, they did suggest that there is an intuitive 
benefit to reducing treatment delay.  In particular, they highlighted the effect of 
delays on patient quality of life.  They further concluded that the waiting times 
observed in their centres were unacceptably long.  
 
INTERDISCIPLINARY TEAMS IN CANCER CARE   
Several international studies have concluded that a multidisciplinary 
approach should be pursued in order to reduce waiting times in lung cancer (Bozcuk 
& Martin, 2001; Jensen et al., 2002; Koyi, Hillerdal, & Brandén, 2002a; Myrdal et 
al., 2004; Salomaa et al., 2005). Several bodies governing the treatment of lung 
cancer have also advocated using multidisciplinary patient management, including 
the British Thoracic Society and the American College of Chest Physicians (British 
Thoracic Society, 1998; Alberts, Bepler, Hazelton, Ruckdeschel, & Williams, 2003).  
A multidisciplinary approach is becoming an increasingly popular strategy in order 
to coordinate patient care by the various specialists involved in the treatment of all 
types of cancer. However, multidisciplinary cancer clinics and conferences have not 
been widely or systematically adopted in the Canadian health care system (Wright, 
De Vito, Langer, Hunter, & Expert Panel on Multidisciplinary Cancer Conference 
Standards, 2006). 
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Many of the aforementioned studies (Billing & Wells, 1996; Bozcuk & 
Martin, 2001; Jensen et al., 2002; Koyi et al., 2002b; Myrdal et al., 2004; Salomaa et 
al., 2005; Liberman et al., 2006) conclude that in order to reduce waiting times, a 
multidisciplinary approach should be pursued. Multidisciplinary teams have been 
recommended in order to manage the care of patients and to coordinate the various 
specialists involved in the treatment of all types of cancer (Riedel, Wang, 
McCormack, Toloza, Montana et al., 2006). This approach has been advocated by a 
number of organizations involved in the treatment of lung cancer, including the 
British Thoracic Society, the American College of Chest Physicians, and Cancer 
Care Ontario (British Thoracic Society, 1998; Alberts et al., 2003; Wright et al., 
2006).   
There are a variety of characterizations of a multidisciplinary team in the 
literature.  A multidisciplinary team has been described as:  
A group of people of different health-care disciplines, 
which meets together at a given time to discuss a given 
patient and who are each able to contribute independently to 
the diagnostic and treatment decisions about the patient. 
(Fleissig, Jenkins, Catt, & Fallowfield, 2006)  
 
A multidisciplinary approach to cancer care “involves collaboration between team 
members and treatment planning, and is more likely to be patient-centered and to 
provide psychosocial support and access to clinical trials.” (Houssami & Sainsbury, 
2006) 
In a document supported by the American College of Chest Physicians, 
Alberts (2003) defines multidisciplinary teams, and clinics, as follows: 
Many groups have attempted to coordinate care through 
multidisciplinary management conferences and multi-
disciplinary clinics. In the latter, physicians from several 
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specialties conduct clinics in the same location at the same 
time. In addition to streamlining the workup and treatment 
planning, multidisciplinary conferences and clinics provide 
a forum for collegial exchange of professional opinions. 
The team approach and consensus development enables the 
consulting physician to convey a clear and consistent 
management opinion to the patient. 
 
A multidisciplinary team will either work in a clinical setting, or meet 
regularly at a multidisciplinary cancer conference (MCC), or both.  Multidisciplinary 
clinics are held at regular intervals in one location where various specialists will see 
patients with a particular type of cancer (Alberts et al., 2003; Ruhstaller, 2006). 
Multidisciplinary cancer conferences refer to meetings held at regular intervals that 
implicate specialists involved in the treatment of a particular type or group of 
cancers. The specialists attending the meeting are variously involved in the 
diagnosis, staging, and treatment of the patients being discussed (Fleissig et al., 
2006; Ruhstaller, 2006).   
 There are divergent criteria for the composition of a multidisciplinary team 
in cancer care. According to the Programme québecois de lutte contre le cancer, a 
regional interdisciplinary team specializing in a particular tumor site must consist of 
a nurse specialized in oncology, a medical oncologist, a physician, a pharmacist 
specialized in oncology, a psychologist specialized in oncology, a social worker 
specialized in oncology, a radiation oncologist, a radiologist, a pathologist, a 
surgeon specialized in the tumor site, a dietitian specialized in oncology, 
rehabilitation specialists, and a representative from palliative care services 
(Direction de la lutte contre le cancer, 2005). According to Fleissig (2006), the 
composition of a multidisciplinary team will vary according to the tumor site, but 
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may include “surgeons, diagnostic and therapeutic radiologists, histopathologists, 
medical and clinical oncologists, nurse specialists, and palliative-care physicians.”  
Multidisciplinary teams may impact waiting times both positively and 
negatively. A multidisciplinary approach to the treatment of cancer is thought to 
improve the speed and continuity of patient care by facilitating communication 
among specialists, which ultimately reduces intervals between consultations and 
treatments.  It is also thought to increase the likelihood that each patient receives the 
appropriate treatment for his condition, given that a variety of specialist opinions are 
solicited during the diagnostic and treatment pathway (Newman et al., 2006). It has 
also been suggested that multidisciplinary one-stop clinics reduce the number of 
visits required by each patient during the diagnostic work-up phase (Fleissig et al., 
2006).  Regular multidisciplinary meetings improve the coordination of patient care 
by encouraging efficient treatment planning and referral among specialists, and 
reducing the likelihood of duplicate exams being performed.  All of these elements 
are thought to improve clinical outcomes for patients (Fleissig et al., 2006). 
Compared to independent treatment decisions by the primary oncologist, the 
presentation and discussion of each patient’s case in MCCs may lead to lengthier 
waiting times.  However, in complicated cases multidisciplinary discussion of 
treatment has been shown to be beneficial to the patient’s overall treatment plan 
(Newman et al., 2006). 
 There are divergent criteria for the composition of a multidisciplinary team 
in cancer care. According to the Programme québecois de lutte contre le cancer, a 
regional interdisciplinary team specializing in a particular tumor site must consist of 
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a nurse specialized in oncology, a medical oncologist, a physician, a pharmacist 
specialized in oncology, a psychologist specialized in oncology, a social worker 
specialized in oncology, a radiation oncologist, a radiologist, a pathologist, a 
surgeon specialized in the tumor site, a dietitian specialized in oncology, 
rehabilitation specialists, and a representative from palliative care services 
(Direction de la lutte contre le cancer, 2005). According to Fleissig (2006), the 
composition of a multidisciplinary team will vary according to the tumor site, but 
may include “surgeons, diagnostic and therapeutic radiologists, histopathologists, 
medical and clinical oncologists, nurse specialists, and palliative-care physicians.”  
Although the majority of current literature uses the term “multidisciplinary”, 
the term “interdisciplinary” is the term adopted by the PQLC, which it is promoting 
as a target for cancer care in Québec (Direction de la lutte contre le cancer, 2005):  
En oncologie, le travail interdisciplinaire vise 
essentiellement à accroître la qualité des soins aux 
personnes atteintes de cancer et aux proches (la cible 
commune) en combinant l’expertise unique de chacune 
des professions. L’équipe interdisciplinaire ne se résume 
donc pas à un regroupement permanent d’un ensemble 
de spécialistes effectuant des tâches en série (ce qui 
correspondrait davantage au concept de 
multidisciplinarité), mais exige en plus une synthèse et 
une concertation entre les points de vue qui s’intègrent 
en un tout cohérent.  
 
 Just as the evidence surrounding the role of delays in lung cancer survival is 
unclear, so is evidence of the benefit of multidisciplinary teams. Although the 
introduction of multidisciplinary teams (MDTs) in lung cancer has been shown to 
reduce waiting times from the initial consultation to treatment (Deegan et al., 1998), 
to increase the number of patients receiving chemotherapy (Forrest, McMillan, 
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McArdle, & Dunlop, 2005), and to improve survival (Forrest et al., 2005),  MDTs 
have also been demonstrated to have no beneficial impact on the timeliness of 
diagnostic and treatment decisions (Riedel, Wang, McCormack, Toloza, Montano et 
al., 2006). However, the studies in question are small in scale and the 
methodological design in Riedel’s study (2006) is questionable. The analysis of non-
multidisciplinary team management was done following the closing of a 
multidisciplinary clinic. The infrastructure from the multidisciplinary clinic 
remained in place, namely the weekly multidisciplinary meetings and the electronic 
database. The authors admit that the impact of these features on the non-
multidisciplinary clinic is not negligible.  
Changes in patient management using multidisciplinary teams have occurred 
in parallel with other major changes in cancer treatment including improved 
treatment options, better detection of cancer, and the adoption of evidence-based 
guidelines for treatment (Fleissig et al., 2006).  Consequently, it is difficult to 
ascribe success to a single aspect of this multifaceted change.  
 
THE INTERDISCIPLINARY PULMONARY ONCOLOGY 
PROGRAM AT THE JEWISH GENERAL HOSPITAL 
The interdisciplinary Pulmonary Oncology Program at the Jewish General 
Hospital incorporates professionals from oncology, pulmonary medicine, nursing, 
thoracic surgery, pathology, radiology, radiation therapy, dietetics, psycho-oncology 
and physiotherapy into deciding the care plan for each newly diagnosed lung cancer 
patient. It is centered on a weekly interdisciplinary meeting, wherein all the 
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aforementioned professionals discuss new and ongoing cases, and the care plan is 
decided by consensus.   
Each patient has a primary pulmonary oncologist and a nurse assigned to 
their care, and all major treatment decisions are discussed in the weekly 
interdisciplinary meeting.  Each patient’s treatment plan or any ongoing treatment 
issue is summarized in a letter that is included in the patient’s chart and sent to other 
professionals involved in the patient’s care, such as their family physician. Patients 
are seen for follow-up by their pulmonary oncologist-nurse team in one of several 
weekly clinics, and are referred to other members of the interdisciplinary team as 
required or requested. 
There are various points of entry to the pulmonary oncology program for 
patients with a suspected or known lung cancer. Patients may either be directly 
referred from a general practitioner, other pulmonologist or oncologist, other 
referring hospital, or self-referral by the patient requesting a second opinion with 
possible transfer of care.  Annex 1a outlines the trajectory of an average patient seen 
in the pulmonary oncology program.   A simplified version of Annex 1 will be used 
in Sections 3 and 4.  Annex 1b outlines the trajectory of early-stage patients who 
have received curative surgery prior to visiting the pulmonary oncology clinic.    
The majority of patients referred by general practitioners with a suspected 
diagnosis are done so on the basis of physical findings, and/or history with an 
abnormal chest-x-ray sometimes following several courses of ineffective antibiotic 
therapy. Some have already had a CT scan performed. The remainder of those 
referred either by specialists within the hospital, or those from other centers and 
37 
 
regions, will more commonly already have more advanced imaging (CT scan, MRI, 
PET scan) and diagnostic testing performed prior to referral. 
Patients with a possible lung cancer or known diagnosis receive 
interdisciplinary care very early on in the referral process or hospital interaction. 
This may occur at the first visit or admission, or after the patient is presented at the 
interdisciplinary meeting where their case is assigned to a nurse specializing in 
oncology. The referred patient is presented at the interdisciplinary cancer conference 
where all facets of their case are discussed, a plan is formulated and a nurse assigned 
if not already involved. Patients are followed throughout their illness trajectory and 
wherever their needs place them. Patients with lung cancer may be admitted to 
hospital on many occasions to manage complications of treatment and illness. When 
admitted, their primary physician and nurse, who interact directly with the admitting 
team and provide continual support to the patient and family, see the patient on a 
regular basis.  
For the purposes of this study, the team at the Jewish will be referred to as 
interdisciplinary, as defined by the PQLC. However, given that interdisciplinary is 
not a term of art, and given that multidisciplinary is the term most often seen in the 
scientific literature on this topic, interdisciplinary and multidisciplinary will be used 
interchangeably to refer to a group of professionals from various specialties working 
collaboratively in the diagnosis, treatment, and care of patients with cancer.    
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STUDY DESIGN          
 This study is an audit of clinical performance of a lung cancer program at a 
single centre.  The study was designed as such in order to identify strengths and 
weaknesses in clinical service delivery, and to identify areas of future focus.  In 
order to complete this preliminary audit in a timely manner, information was 
collected from the existing patient database managed by the pulmonary oncology 
division. Institutional approval was granted for the use of the database. 
 
INCLUSION AND EXCLUSION CRITERIA     
The cohort consists of patients with primary lung cancer seen by the 
interdisciplinary team at the Jewish General Hospital (JGH) in Montreal, Québec, 
between January 1, 2004 and December 31, 2007. Patients without a confirmed 
histological diagnosis of lung cancer, patients with a diagnosis of primary cancer 
other than NSCLC or SCLC, patients transferred to the JGH after having begun 
treatment at an outside facility, and patients who were seen in second opinion and 
who returned to their referring facility were excluded from the study. These patients 
were excluded in order to maintain the focus on the provision of services within the 
pulmonary oncology program at the JGH.  Excluding outside factors and ensuring a 
focus on the clinical performance within the JGH enhances the internal validity of 
the study.  
 Since this study examines the quality of clinical services at a single centre, its 
external validity is limited.  However, the time intervals employed for the analysis, 
particularly the R-FT interval, were designed to be comparable to provincial, 
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national and international guidelines.  As such, the waiting times achieved at the 
JGH can be compared to the waiting times at any other hospital in Quebec or across 
Canada, provided that the other sites are using the same reporting criteria. Moreover, 
this study may prove useful to other sites by describing a model of interdisciplinary 
management, and by highlighting both the successes and areas of improvement for 
the pulmonary oncology program. 
 
DATA COLLECTION         
The pulmonary oncology program maintains an approved database 
containing demographic, diagnostic and treatment information for all patients, which 
is transcribed from patient charts.  All of the data used for this retrospective study 
was extracted from the pulmonary oncology database, with the approval of the 
Research Ethics Committee at the Jewish General Hospital.   
 
VARIABLES          
Demographic variables 
 The demographic variables extracted from the database are listed in Table 8. 
 
Dates and Time Intervals 
The time intervals examined in this study were chosen in order to create 
indicators comparable to existing guidelines.  A description of the dates of certain 
key points along a patient’s clinical trajectory and the time intervals calculated from 
those dates is described in Table 9.  Figure 3 outlines the trajectory of a typical lung 
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cancer patient seen at the Jewish General Hospital.  Refer to Annex 1a to view a 
more detailed clinical trajectory. Further explanation of time intervals is provided 
following Table 9. 
 
Table 8: Patient characteristics 
Variable Type Description 
Sociodemographic  
Gender Categorical 
 
Date of birth Date 
 
Proximity to 
hospital 
Categorical <20km, 21-50km, 51-100km, >100 km 
Patient status Categorical New patient, recurrent disease, second 
opinion 
First contact with 
pulmonary 
Categorical Referral from GP or specialist, referral 
from Emergency Department, in-hospital 
consultation 
Age at diagnosis Continuous, 
Categorical  
(<65, 65-75 >75) 
Calculated by subtracting date of birth from 
date of diagnosis 
 
Diagnosis  
Diagnosis Categorical NSCLC or SCLC 
 
Date of diagnosis Date Date of diagnostic procedure leading to 
diagnosis 
 
NSCLC subtype Categorical Adenocarcinoma, squamous cell 
carcinoma, large cell BAC, mixed, 
undifferentiated 
Stage Categorical NSCLC: I through IV  
SCLC: limited or extensive) 
ECOG 
Performance 
Status (see note 1) 
Categorical 0-3 
Performance status was assessed at the 
patient’s first consultation with a 
pulmonary physician 
Smoking status Categorical Smoker (continues to smoke or quit less 
than one month)  
Ex-smoker 
Never-smoker (<100 cigarettes over 
lifetime) 
Smoking status was assessed at the 
patient’s first consultation with a 
pulmonary physician 
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Treatment 
First treatment Categorical Chemotherapy, Radiation, Surgery, 
Supportive care 
Treatment 
received 
Categorical Double agent chemotherapy, single agent 
chemotherapy, palliative radiation, 
definitive radiation, etc. 
 
Table 9: Date and Time interval variables 
Variable Type Description 
Date of first 
contact 
Date Date of first consultation with the 
pulmonary service, either in the pulmonary 
outpatient clinic, emergency department, or 
in-hospital 
Date of first 
treatment 
Date Date of initiation of first treatment, either 
chemotherapy, surgery, or radiation.  
Patients receiving supportive care are not 
given a date of first treatment 
Date of first 
meeting 
Date Date of the first discussion of the patient’s 
case at the interdisciplinary cancer 
conference (ICC) 
Decision to treat 
(DTT) 
(see note 2) 
Date Date of the decision to initiate treatment, 
made in the interdisciplinary cancer 
conference.  If this date is unavailable, the 
date of the decision as noted by the treating 
physician in the patient’s chart 
Ready to treat 
(RTT) 
(see note 2) 
Date Date of the patient’s readiness to begin 
treatment, after any planned delays are over  
Date of death 
 
Date Date of death from cancer-related causes 
FC-D 
 
Continuous Interval between first consult with 
pulmonary and diagnosis 
D-FT Continuous Interval between diagnosis and initiation of 
first treatment 
D-DT Continuous Interval between diagnosis and decision to 
treat.  
R-FT 
 
Continuous Interval between ready to treat and first 
treatment 
FC-FT  Continuous Interval between first consultation with 
pulmonary service and initiation of first 
treatment.   
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Note 1: The Eastern Cooperative Oncology Group (ECOG) Performance Status is a 
scale that is used to assess how cancer affects the daily activities and function of the 
patient.  It is assessed by the treating physician and is used to determine treatment 
options and prognosis (Oken et al., 1982). 
 
Note 2: Decision to treat (DTT) is the date of the interdisciplinary meeting in which 
a consensus decision on treatment was made.  If this date is unavailable, it is the date 
the primary physician noted the treatment decision in the patient’s chart.  For 
surgical patients not seen in the pulmonary outpatient clinic prior to surgery, DTT is 
the date of the first visit to the thoracic surgeon. In line with the Cancer Care Ontario 
reporting system, the Ready to Treat (RTT) date is generally the same as the DTT, 
except in cases where there is a planned treatment delay for a personal or medical 
reason, for instance for travel or while the patient is recovering from an invasive 
diagnostic procedure (Cancer Care Ontario, 2006). 
 
The results for the following intervals are presented in Section 4.  
 
Figure 3: Clinical trajectory of typical lung cancer patient 
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44 
Interval FC-D: From first consultation to diagnosis  
Patients may have their first consultation with the pulmonologist either in the 
outpatient clinic, emergency department, or in-hospital. The date of diagnosis was 
considered the date that the successful diagnostic procedure was performed, rather 
than the date it was reported.  
 
Interval R-FT: From ready to treat to first treatment 
This interval represents the period after all of the staging procedures had 
been completed, the decision to treat had been made, and any planned delays were 
completed. During this period the patient’s treatment is scheduled (in consultation 
with the patient) and any pre-treatment investigations are completed.   
 
Interval D-FT: From diagnosis to first treatment 
 This interval includes all staging procedures, treatment decisions, and 
treatment scheduling. 
 
Interval FC-FT: From first consultation to first treatment 
 This interval includes the entire clinical trajectory of the patient at the 
treatment facility, referred to as the Hospital delay in other published reports 
(Myrdal et al., 2004; Devbhandari, Soon et al., 2007; Rolke et al., 2007).  Patients 
were classified according to the first treatment they received in order to assess the 
waiting period for each particular service.  In the small number of cases where the 
patient received multimodality first treatment, for example concurrent 
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chemotherapy/radiotherapy, the patient was classified according to the date that the 
first treatment that was initiated. The number of patients receiving multimodality 
therapy was too small to assess its effect independently.   
 
The results for the following intervals are presented in Annex 2. 
 
Interval D-ICC: From diagnosis to presentation at interdisciplinary cancer 
conference 
 Patient cases were presented at the weekly interdisciplinary cancer 
conference where each new patient’s treatment plan was discussed.  They may have 
been presented multiple times during the staging period in complicated cases.  This 
interval measures the time from diagnosis to the initial presentation at the 
interdisciplinary cancer conference.   
 
Interval ICC-DTT: From initial presentation at interdisciplinary cancer conference 
to decision to treat 
Decision to Treat (DTT) was defined as the date of the interdisciplinary 
meeting in which a consensus decision on treatment was made.  For most patients, 
the treating pulmonary oncologist was the pulmonologist and he was present at the 
meeting in which the DTT was made.  In the few cases where the treatment decision 
was not made at the interdisciplinary meeting, it was the date the primary 
pulmonologist noted the treatment decision in the patient’s chart. For surgical 
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patients not seen in the pulmonary outpatient clinic prior to surgery, DTT was the 
date of the first visit to the thoracic surgeon.  
 
Interval DTT-R: From decision to treat to ready to treat 
The RTT date was usually the same as the DTT date, except in cases where 
there was a planned treatment delay. Planned delays may have been for personal or 
medical reasons, for instance for travel or while the patient was recovering from an 
invasive diagnostic procedure(Cancer Care Ontario, 2006). 
 
Tumor histology 
Analysis of waiting time intervals was done separately for patients with 
SCLC and NSCLC. Given the distinct clinical features of NSCLC and SCLC and the 
varying responses to treatment based on histology, a suspicion of SCLC based on 
imaging or paraneoplastic features should prompt a more rapid workup and staging. 
Therefore it was necessary to examine clinical intervals for these groups of patients 
separately. 
 
Comparison with existing guidelines  
In order to compare the service at the JGH with Cancer Care Ontario priority 
guidelines (Cancer Care Ontario, 2006), patients were classified according to  
diagnosis and  treatment modality. Patients were separated according to histologic 
type as described above. The radiation therapy was also classified into palliative and 
curative categories as per the CCO guidelines. 
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For instance, patients receiving chemotherapy were prioritized according to 
diagnosis; SCLC patients received a priority II classification whereas NSCLC 
patients received a priority III classification.  Patients receiving radiotherapy were 
prioritized according to the type of treatment they received; patients receiving 
palliative radiotherapy received a priority II classification, whereas patients 
receiving radiotherapy that required complex planning (ie. radical or combined 
chemotherapy-radiation therapy) received a priority III classification. 
Patients were classified according to the first treatment they received in order 
to assess the interval within which a particular service was provided.  In the few 
cases where the patient received multimodality first treatment, for example 
concurrent chemo/radiotherapy, the patient was classified according to the date of 
the first treatment that was initiated. Therefore a patient who received chemotherapy 
prior to the initiation of their radiotherapy was classified as having chemotherapy as 
their first treatment.   
 
GUIDELINES USED FOR COMPARISON     
 Pertinent sources were required in order to fulfil the objective of assessing 
waiting times achieved at the Jewish General Hospital against existing guidelines.  
As there are a number of recommendations in existence, and even more in 
development, the selection of appropriate guidelines required a judicious approach.  
Justification for the use of each set of guidelines is set out below.  
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British Thoracic Society guidelines 
 This set of guidelines was chosen because it is specific to the diagnosis, 
staging, and treatment experience of lung cancer patients.  Furthermore, the BTS 
guidelines have been assessed by a number of other international studies(Salomaa et 
al., 2005; Riedel, Wang, McCormack, Toloza, Montana et al., 2006; Rolke et al., 
2007; Gould et al., 2008), which provides a point of comparison in the scientific 
literature for our population relative to other lung cancer services around the world. 
 
Cancer Care Ontario guidelines 
 This set of guidelines was chosen because it is the only comprehensive set of 
guidelines for cancer treatment in existence in Canada. It is the only set of guidelines 
that provides waiting time intervals for all treatment modalities, namely 
chemotherapy, radiation therapy, and surgery.  Assessing the service at the Jewish 
General Hospital against guidelines developed in Canada is an essential exercise, 
given the growing movement towards establishing benchmarks for waiting times 
across the country, and also given their relevance to the healthcare experience in 
Canada.  Since there are no comprehensive pan-Canadian guidelines in existence, 
Cancer Care Ontario’s were chosen. 
 
Pan-Canadian benchmarks for radiation therapy 
 This benchmark was chosen because it is the only one that has been adopted 
across the country. Although provinces and territories are moving towards 
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comprehensive waiting time guidelines, progress has been slow.  To date, the only 
agreement has been on radiation therapy waiting times.  Assessing the service at the 
JGH against this benchmark is valuable, as it situates the JGH’s performance against 
what is expected across Canada. 
 The remaining recommendations discussed in Section 2, those of the 
Swedish Lung Cancer Study Group (SLCSG) and those of the Wait Time Alliance 
(WTA), were not chosen for comparison for several reasons.  Firstly, the SLCSG 
guidelines were not as well studied as the BTS guidelines in the literature, and given 
that both the BTS and SLCSG guidelines were international guidelines specific to 
lung cancer, the latter were not chosen in order to avoid redundancy and because 
they were less well known than the BTS guidelines.  The WTA guidelines were not 
chosen because they, like the pan-Canadian guidelines for radiation therapy, 
addressed waiting times for radiation therapy in Canada.  Given that the pan-
Canadian guidelines were adopted by all the provinces and thus represent an official 
commitment to waiting times, whereas the WTA guidelines do not, they were not 
chosen for comparative purposes.  However, both the SLCSG and WTA guidelines 
are briefly discussed in Section 5. 
 
FOCUS GROUP          
 A focus group composed of oncologists, pulmonary physicians, nurses, 
respiratory technicians, and other allied health professionals (n=26) was conducted 
on June 19, 2008.  The interdisciplinary group was asked their opinion on 
appropriate waiting times for each of the intervals described above, as well as an 
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estimate of the length of each interval for patients seen at the JGH. They were then 
presented with the results of a preliminary analysis of each of the intervals.  The 
group was also asked their opinion of the utility of existing benchmarks and 
guidelines in the clinical management of lung cancer patients.   Results of the focus 
group discussion can be found in Annex 2. 
 
STATISTICAL ANALYSIS        
Means, medians and interquartile ranges (IQR) were used to summarize the 
patient characteristics and time interval variables. Patients achieving negative 
intervals, for example -5 days from first consultation to diagnosis, indicating a 
deviation from the trajectory outlined in Figure 1, were excluded from the 
calculation of mean and median waiting times for the interval in question. For each 
of the CCO and BTS comprehensive treatment guidelines, patients were assigned the 
binary variable (0=no, 1=yes) according to whether they were seen within the 
recommended waiting period for their treatment modality for the R-FT interval.  
Tests of independence were conducted to determine the level of contingency 
between BTS and CCO results.  The characteristics of patients falling within and 
outside recommended guidelines were first examined in univariate analysis using 
Pearson χ2 tests.  Variables examined included age, histological diagnosis, stage, 
first consult, first treatment, and ECOG performance status. Multiple logistic 
regression analysis was used to identify waiting time predictors. Patients were 
dichotomized as above, according to whether they were seen within recommended 
guidelines. The same variables used in univariate analysis were used as covariates. A 
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p-value of <0.05 was considered significant.  Odds ratios and 95% CI were 
calculated for each of the variables in the model. All analysis was performed using 
SPSS software.  
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WAITING TIMES IN THE CLINICAL TRAJECTORY OF 
PATIENTS WITH LUNG CANCER 
 
Abstract 
Background: National waiting time guidelines for all types of cancer treatment have 
not yet been developed in Canada. This study was performed to compare the waiting 
times achieved at the Jewish General Hospital (JGH) in Montreal, Québec with 
existing guidelines from Ontario and Britain, and to determine the predictors of 
longer waiting times among lung cancer patients at the JGH. 
Methods: 473 patients diagnosed with non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC) between 2004 and 2007 were included in the cohort.  
Patients were classified according to the date of first treatment (chemotherapy, 
radiotherapy, surgery, or supportive care). Waiting time distributions were 
calculated for patient subgroups. Waiting times were compared to existing 
guidelines from the British Thoracic Society and Cancer Care Ontario, as well as 
national radiotherapy benchmarks, in order to determine the proportion of patients 
meeting recommendations. Multiple logistic regression was used to determine 
factors associated with the waiting times of patients not meeting guidelines. 
Results: Patients with SCLC had significantly shorter waiting times than patients 
with NSCLC.  Adherence to guidelines varied substantially according to treatment 
and among the guidelines studied. Patients aged 65 to 75 were 1.9 times less likely 
than patients under 65 to meet BTS guidelines; patients with early stage disease, and 
patients with NSCLC were 1.9 and 2.1 times less likely, respectively, to meet the 
BTS guidelines for waiting time treatment.  
Conclusions: A large proportion of patients undergoing chemotherapy and surgery 
are seen within recommended waiting times. There were weaknesses in achieving 
recommended waiting times for radiation therapy, as well as weaknesses in treating 
elderly patients, patients with early-stage disease and patients with good 
performance status within recommended guidelines. Any reductions in waiting times 
should be balanced against the need for thorough investigation and staging of each 
patient prior to initiating treatment.  
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Introduction 
Lung cancer is the leading cause of cancer death in North American men and 
women, accounting for an estimated 23,300 incident cases and 19,900 deaths in 
Canada and 213,000 incident cases and 160,000 deaths in the United States in 2007 
(American Cancer Society, 2007; Canadian Cancer Society, 2007). The management 
of the patient with suspected lung cancer requires staging by means of appropriate 
imaging and tissue confirmation, usually by bronchoscopy performed by a 
pulmonary specialist. Following this the patient is referred to a medical oncologist, 
radiation oncologist, specialized pulmonary oncologist or thoracic surgeon 
depending on the stage and perceived initial treatment.  Given the poor prognosis 
and symptom burden of the disease, timely access to treatment and quality care are 
essential to the well being of these patients. 
Treatment delays in all areas of the Canadian health care system have earned 
a great deal of public attention in recent years (Wait Time Alliance for Timely 
Access to Health Care, 2005; Canadian Institute for Health Information, 2006; 
Canadian Breast Cancer Network, 2008).  Waiting time targets for cancer care are 
among the priority areas currently being developed by the federal and provincial 
governments (Sullivan, 2006a; Winget et al., 2007). However, there is a shortage of 
research, reporting, and collaboration on waiting times in cancer care (Sullivan, 
2006a; Winget et al., 2007), which might provide guidance to provincial agencies in 
establishing standards for medically acceptable treatment times. Consequently, 
waiting time guidelines are based on management targets rather than on clinical 
evidence (Cancer Care Ontario, 2006; Schaafsma, 2006; Sullivan, 2006a), and 
  
55 
provincial reporting is un-standardized and inconsistent (Canadian Institute for 
Health Information, 2006).   
Relatively little is known about waiting times for the treatment of lung 
cancer in Canada, particularly among patients with advanced stages of disease who 
represent the majority of cases. Although efforts to reduce waiting times are being 
pursued irrespective of cancer type, the impact of waiting time reduction in lung 
cancer will be especially important given the rapid progression of the disease and the 
role of timely treatment on symptom palliation and tumor control (Billing & Wells, 
1996; O'Rourke & Edwards, 2000; Bozcuk & Martin, 2001; Jensen et al., 2002; 
Koyi et al., 2002b; Moody et al., 2004; Myrdal et al., 2004). 
The use of interdisciplinary teams, comprised of the previously mentioned 
specialists along with other allied health professionals, has been proposed as a 
strategy to reduce waiting times. Such teams in the management of breast cancer 
patients have led to improved outcomes in treatment delays and patient satisfaction 
(Gabel, Hilton, & Nathanson, 1997), and there is some evidence to suggest that 
interdisciplinary management of lung cancer patients is equally beneficial (Deegan 
et al., 1998; Conron et al., 2007; Devbhandari, Bittar et al., 2007). 
The interdisciplinary pulmonary oncology program at the Jewish General 
Hospital incorporates professionals from oncology, pulmonary medicine, nursing, 
thoracic surgery, pathology, radiology, radiation therapy, dietetics, psycho-oncology 
and physiotherapy into deciding the care plan for each newly diagnosed lung cancer 
patient. It is centered on a weekly interdisciplinary meeting, wherein all the 
aforementioned professionals discuss new and ongoing cases, and the care plan is 
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decided by consensus.  Each patient has a primary pulmonary oncologist and a nurse 
assigned to their care, and all major treatment decisions are discussed in the weekly 
interdisciplinary meeting.  The pulmonary oncology program maintains an electronic 
database consisting of a demographic, clinical and pathological profile of each 
patient.  
 The objectives of this study were: (1) to audit the performance of the 
interdisciplinary pulmonary oncology service at the Jewish General Hospital with 
respect to waiting times for key intervals and subgroups of patients; (2) to compare 
waiting times with existing guidelines; and (3) to determine those factors associated 
with longer waiting times in this population.  
Since comprehensive cancer care waiting time guidelines remain in the 
development stage in the majority of provinces, the guidelines used in this analysis 
to evaluate the performance of the pulmonary oncology program were those 
established by the British Thoracic Society (BTS), Cancer Care Ontario (CCO), and 
pan-Canadian guidelines for radiation oncology (British Thoracic Society, 1998; 
Cancer Care Ontario, 2006; Wait Time Alliance for Timely Access to Health Care, 
2007). 
 The recommendations of the British Thoracic Society were published in 
1998 in order to provide guidance to respiratory physicians in the management of 
lung cancer. The recommendations are based on “considered clinical opinion” 
(British Thoracic Society, 1998) and, where available, published scientific evidence. 
The recommendations of the BTS with respect to waiting times have been cited in a 
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number of international studies (Salomaa et al., 2005; Riedel, Wang, McCormack, 
Toloza, Montana et al., 2006; Rolke et al., 2007; Gould et al., 2008).  
Cancer Care Ontario presented its target waiting time recommendations in 
2006.  The recommendations cover all tumor types and are prioritized based on the 
judgment of the physician. Priority is determined by the urgency of the case and the 
aggressiveness of the tumor (Cancer Care Ontario, 2006). The notations (II) and (III) 
refer to priority levels, with level II being more urgent than level III. Cancer Care 
Ontario recommends that ninety percent of patients be seen within these time 
intervals.  
In 2005, the First Ministers of Canada agreed to a common goal of treating 
radiation patients within 4 weeks of being ready to treat (Ontario Ministry of Health 
and Long-Term Care, 2005).  This is the only common benchmark that has been 
established for cancer care in Canada to date; however, progress towards this 
benchmark is being reported by nearly all provinces and territories (Canadian 
Institute for Health Information, 2007). 
 
Methods 
Inclusion and exclusion criteria 
The cohort consisted of patients with primary lung cancer seen by the 
interdisciplinary team at the Jewish General Hospital (JGH) in Montreal, Québec, 
between January 1, 2004 and December 31, 2007. Patients without a confirmed 
histological diagnosis of lung cancer, those with a diagnosis of lung cancer other 
than non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) were 
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excluded from analysis. Similarly, patients transferred to the JGH after having begun 
treatment at another facility, and those who were seen in second opinion and then 
returned to their referring institution were excluded from the study. These patients 
were excluded in order to maintain the focus on the provision of services within the 
pulmonary oncology program at the JGH.  
 
Data Collection 
All of the data used for this retrospective study was extracted from the 
pulmonary oncology electronic database.  Institutional approval was granted by the 
Research Ethics Committee at the Jewish General Hospital for the extraction of data 
from the study period.  
Proximity to hospital was calculated based on each patient’s borough of 
residence, as declared on his or her hospital card.  An approximate distance from the 
patient’s place of residence was calculated and classified as within 20 km of the 
hospital, 21-50 km from the hospital, 51-100 km from the hospital, or greater than 
100 km from the hospital. 
Staging of patients was achieved using imaging (CT, PET scans) presented at 
the interdisciplinary cancer conference, and determined according to the current 
staging classification (Mountain, 1997).   
 
Comparison with existing guidelines  
Cancer Care Ontario recommends that priority levels for urgency of 
treatment are left to the judgment of the physician (Cancer Care Ontario, 2006). In 
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this study, patients were categorized as priority II if they were diagnosed as SCLC or 
if they required aggressive palliative radiation.  Patients were assigned to priority III 
if they were diagnosed as NSCLC or if they required curative radiation involving 
extensive planning.  
 
Time Intervals  
Time intervals examined in this study were chosen in order to create 
indicators comparable to the guidelines being used. BTS and CCO guidelines 
recommend intervals for the period from referral to a specialist to first specialist 
consultation, as well as for the period from ready to treat to first treatment.  As the 
systematic collection of referral data at the JGH began only in January 2006, this 
interval was not available for analysis for all study patients.  Therefore, the first time 
point in this study was the first consultation with a pulmonary specialist. This study 
intended to examine the provision of pulmonary oncology services at the Jewish 
General Hospital and therefore did not consider earlier delays such as time from first 
symptom to first medical consultation.  Figure 1 illustrates the clinical intervals in 
the treatment trajectory. 
 
Interval FC-D: From first consultation to diagnosis  
Patients may have their first consultation with the pulmonologist either in the 
outpatient clinic, emergency department, or in-hospital. The date of diagnosis was 
considered the date that the successful diagnostic procedure was performed, rather 
than the date it was reported.  
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Interval R-FT: From ready to treat to first treatment 
This interval represents the period after all of the staging procedures had 
been completed, the decision to treat had been made, and any planned delays were 
completed. During this period the patient’s treatment is scheduled (in consultation 
with the patient) and any pre-treatment investigations are completed.   
 
Interval D-FT: From diagnosis to first treatment 
 This interval includes all staging procedures, treatment decisions, and 
treatment scheduling. 
 
Interval FC-FT: From first consultation to first treatment 
 This interval includes the entire clinical trajectory of the patient at the 
treatment facility, referred to as the Hospital delay in other published reports 
(Myrdal et al., 2004; Devbhandari, Soon et al., 2007; Rolke et al., 2007).  Patients 
were classified according to the first treatment they received in order to assess the 
waiting period for each particular service.  In the small number of cases where the 
patient received multimodality first treatment, for example concurrent 
chemotherapy/radiotherapy, the patient was classified according to the date that the 
first treatment that was initiated. The number of patients receiving multimodality 
therapy was too small to assess its effect independently.   
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Tumor histology 
  Given the distinct clinical features of NSCLC and SCLC and the varying 
responses to treatment based on histology, the analysis of waiting time intervals was 
done separately for patients with SCLC and NSCLC.  
 
Statistical analysis  
Means, medians and interquartile ranges (IQR) were used to summarize the 
patient characteristics and time interval variables. Patients achieving negative 
intervals, for example -5 days from first consultation to diagnosis, indicating a 
deviation from the trajectory outlined in Figure 1, were excluded from the 
calculation of mean and median waiting times for the interval in question. For each 
of the CCO and BTS comprehensive treatment guidelines, patients were assigned the 
binary variable (0=no, 1=yes) according to whether they were seen within the 
recommended waiting period for their treatment modality for the R-FT interval.  
Tests of independence were conducted to determine the level of contingency 
between BTS and CCO results.  The characteristics of patients falling within and 
outside recommended guidelines were first examined in univariate analysis using 
Pearson χ2 tests.  Variables examined included age, histological diagnosis, stage, 
first consult, first treatment, and ECOG performance status.  Multiple logistic 
regression analysis was used to identify waiting time predictors.  Patients were 
dichotomized as above, according to whether they were seen within recommended 
guidelines. The same variables used in univariate analysis were used as covariates. A 
p-value of <0.05 was considered significant.  Odds ratios and 95% CI were 
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calculated for each of the variables in the model. All analysis was performed using 
SPSS software.  
 
Results 
Patient characteristics 
 Five hundred and fifty-eight patients with a diagnosis of primary NSCLC or 
SCLC were seen by the pulmonary service at the Jewish General Hospital between 
January 1, 2004 and December 31, 2007.  Eighty-five patients were excluded from 
the analysis. Fifty-six patients were excluded because they transferred their 
treatment to the JGH after having begun at another facility, and another 26 patients 
were excluded because they returned to their referring facility after seeking second 
opinion at the JGH.  Three patients were excluded because their date of diagnosis 
occurred after closure of the study.   
Table 1 shows the characteristics of the 473 patients included in the study. 
The mean age at diagnosis was 67(±11) years (range 31 to 94 years). There were no 
significant differences in the demographic features of SCLC patients as compared to 
NSCLC patients.  Treatment information was available for 468 (99%) patients; of 
those, four patients refused treatment and follow-up, and three others died prior to 
receiving treatment. 
Table 2 shows the treatments received by the remaining 461 patients. 401 
(87%) patients received active treatment. Two hundred sixty-four (85%) patients 
with advanced stage (NSCLC Stage IIIB+/IV and SCLC EXT) received active 
treatment.  
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Waiting time intervals 
Over the course of the study period (2004-2007) there was no significant 
change from year to year in the waiting time for each of the treatment intervals. As 
there were no significant differences over time in the number of patients consulted, 
proximity to hospital, length of waiting intervals, place of workup, and histology, the 
results from all years of the study were combined for the following analysis. 
One-third (33%) of surgical patients were initially investigated by a thoracic 
surgeon, with a diagnosis made at the time of resection.  These individuals were 
referred to the pulmonary oncology team following diagnosis, and therefore had a 
clinical trajectory that varied from most other patients.  They were excluded from 
the calculation of all of the intervals except the interval R-FT. 
As detailed below, the number of cases available for the analysis of waiting 
times varied between 297 and 371. 
 
Interval FC-D: From first consultation to diagnosis  
 Of the 461 patients, 38 surgical patients referred to the pulmonary oncology 
service after their procedure, and 68 patients with a tissue diagnosis prior to their 
first visit with a JGH pulmonologist were excluded for having a negative interval. 
An additional 15 patients were excluded for missing data. The median waiting time 
from first consultation to diagnosis for the remaining 340 patients was 14 days (IQR 
6-37 days).  Eighty percent of patients had a diagnosis within six weeks of their first 
consultation with a pulmonologist.  For patients with NSCLC (n=306) the median 
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time was 14 days (IQR 6-37 days) and for patients with SCLC (n=34) the median 
time was 8.5 days (IQR 4-19.5 days).   
Patients referred by a family physician or specialist (n=227) waited a median 
of 20 days (IQR 7-45 days) for their diagnosis, whereas patients referred from the 
Emergency department (n=24) waited a median of 12 days (IQR 7-45 days), and 
patients seen in-hospital (n=88) waited a median of 6 days (IQR 2-11 days). Patients 
with advanced stage disease were significantly more likely to be first seen in 
consultation in-hospital (p<0.000).   
 
Interval R-FT: From ready to treat to first treatment 
Of the 461 patients, those receiving supportive care (n=60) were excluded 
from the calculation means and medians for this interval.  A further 30 patients were 
excluded for missing data.  The overall median time from ready to treat to initiation 
of treatment for all patients receiving active treatment (n=371) was 9 days (IQR 6-
15). Two hundred sixty-seven (72%) patients were treated within 14 days of being 
ready to treat and 356 (96%) were treated within 30 days.  Patients with NSCLC had 
a longer median waiting time of 9 (IQR 6-16) days (n=331) than patients with SCLC 
with a median waiting time of 6 (IQR 2-7) days (n=40). There was a significant 
difference in the mean R-FT intervals of patients receiving different treatment 
modalities.  Patients receiving chemotherapy (n=171) had a significantly shorter 
mean waiting time at 10 days (95% CI 9-11 days) than patients receiving 
radiotherapy (n=96) with a mean of 14 days (95% CI 11-14 days) (p=0.003) and 
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patients receiving surgery (n=104) with a mean of 13 days (95% CI 11-15 days) 
(p=0.033).  
Figure 2 demonstrates the median and IQR of Intervals FC-D and R-FT.  
Figure 3 demonstrates the median and IQR of Intervals D-FT and FC-FT.  
 
Interval D-FT: Diagnosis to first treatment 
 Of the 461 patients, those receiving supportive care (n=60), those with no 
tissue diagnosis prior to surgery (n=92) and those treated prior to a confirmation of 
their diagnosis (n=12) were excluded from analysis for reasons described previously.  
The overall median waiting time from diagnosis to first treatment (n=297) was 25 
days (IQR 14-44 days).  For patients receiving chemotherapy (n=175), the median 
waiting time was 25 days (IQR 14-42 days).  For patients receiving radiation therapy 
(n=93), the median waiting time was 24 days (IQR 12.5-39.5 days). For patients 
receiving surgery (n=29), the median waiting time was 42 days (IQR 15-63 days).  
For patients with NSCLC (n=258), the overall median waiting time for 
interval D-FT was 27 days (IQR 15-48 days).  Patients with SCLC (n=39) waited a 
median of 12.5 days (IQR 9-24.5 days) for the D-FT interval.   
Patients first seen in-hospital (n=61) had a shorter waiting time for D-FT, a 
median of 22 days (IQR 10.5-29 days), as compared to patients referred by their 
family physician or specialist (n=213), at 28 days (IQR 15-51 days).  Patients seen in 
the Emergency department (n=20) waited a median of 26 days (IQR 14-39) for the 
D-FT interval.   
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Interval FC-FT: First consultation to first treatment  
Of the 461 patients, patients receiving supportive care (n=60) and surgical 
patients not seen by the pulmonary service prior to their surgery (n=32) were 
excluded from this analysis. A further 12 patients were excluded for missing data. 
The overall median waiting time between first consultation to first treatment for all 
patients (n=357) was 30 days (IQR 20-57 days). Among patients receiving 
chemotherapy (n=172), the median waiting time was 29 days (IQR 20-49.5 days). 
Among patients receiving radiotherapy (n=102), the median waiting time was 31 
days (IQR 19-56 days). Among patients receiving surgery (n=83), the median 
waiting time was 42 days (IQR 20-70 days).  
Patients with NSCLC (n=314) waited a median of 33 days (IQR 21-61.5 
days) for the FC-FT interval, whereas patients with SCLC (n=43) waited a median 
of 14 days (IQR 7-34 days).  
There was no significant difference in the mean waiting times for FC-FT 
among patients receiving chemotherapy, radiotherapy, or surgery.  There was a 
statistically significant (p<0.05) difference in the mean waiting times for FC-FT for 
patients seen in-hospital as compared to patients referred by a family 
doctor/specialist. Mean waiting times for patients seen in hospital (n=72) were 28 
days (median 23 days IQR 10-32 days) versus 48 days (median 30 days IQR 21-63 
days) for patients referred by a family doctor or specialist (n=262).   
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Adherence to waiting time guidelines 
The proportion of patients seen within target waiting times for the R-FT 
interval set by Cancer Care Ontario, the British Thoracic Society, and the pan-
Canadian benchmarks for radiation therapy are shown in Table 3.  The percentage 
of patients adhering to waiting time guidelines varied by treatment modality and 
according to the criteria of each organization. 
  Patients receiving chemotherapy as their first treatment were classified 
according to their histological diagnosis; SCLC patients were priority II and NSCLC 
patients were priority III.  Eighty-one percent of priority II patients received 
chemotherapy treatment within the 7-day period recommended by Cancer Care 
Ontario, with a median waiting time of 5 days.  Seventy-one percent of priority III 
patients received treatment within the 14-day period recommended by CCO, with a 
median wait of 9 days.   
Patients receiving radiation therapy as their first treatment were classified 
according to their disease stage.  Patients receiving urgent palliative treatment were 
classified as priority II whereas patients receiving curative radiation were classified 
as priority III.  Thirty-two percent of priority II patients were treated within the 
recommended waiting time of 7 days, with a median waiting time of 9 days.  Thirty-
three percent of priority III patients were treated within the 14-day period 
recommended by CCO, with a median wait of 22 days. 
Patients receiving surgery were not classified separately according to 
urgency, and therefore all patients were considered priority III.   Ninety-one percent 
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of patients were seen within the recommended 28-day period, with a median wait of 
10 days. 
Patients were not classified according to a priority system for comparison 
with British Thoracic Society guidelines.  Sixty-nine percent of patients receiving 
chemotherapy as their first treatment were seen within the 7 working days 
recommended by the BTS, with a median wait of 8 days.  Seventy-three percent of 
patients receiving palliative radiotherapy were seen within the 14-day period 
recommended by BTS, and seventy-one percent of patients receiving radical 
radiotherapy were seen within the recommended 28 days.  
Ninety percent of patients receiving radiation therapy were seen within the 
pan-Canadian benchmark of 28 days. 
 
Predictors of waiting times 
 Patients were classified according to whether the length of their wait in 
Interval R-FT was within the recommended guidelines of the BTS and CCO.  The 
test for independence revealed a contingency of 74%.  Only the comprehensive 
guidelines were examined in univariate and multiple logistic regression analysis in 
order to assess comparability of guidelines and to assess the role of treatment type 
on the adherence to guidelines.  Since the radiotherapy benchmark focuses on a 
single treatment modality, it was not included in this analysis.  
 In univariate analysis, the variables age, stage, ECOG PS, first consult, first 
treatment and tumor histology were considered. Of those, age, stage, and first 
treatment were significantly associated with adherence to guidelines (p<0.05). In 
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multiple logistic regression analysis, those same variables were considered as 
covariates.  Table 4 outlines the OR (95% CI) for the variables in the model. The 
goodness-of-fit of the model was satisfactory (pHosmer-Lemeshow = 0.98). Patients with 
early stage disease and patients with better performance status were 1.9 and 2.1 
times less likely, respectively, to meet the BTS waiting time guidelines for 
treatment.  Patients aged 65-75 were 1.9 times less likely to meet BTS guidelines 
than patients under 65.  Patients with SCLC were 2.9 times more likely than patients 
with NSCLC to meet BTS guidelines. Patients receiving chemotherapy as a first 
treatment were 4.3 times less likely than patients receiving surgery to meet BTS 
guidelines.  Patients receiving radiotherapy as first treatment were 6.2 times less 
likely than patients receiving surgery to meet the BTS guidelines. 
 
Discussion 
Waiting times for treatment are an indicator of the quality and continuity of 
health care services (Schaafsma, 2006). Establishing and monitoring benchmarks for 
waiting times are important steps in ensuring that cancer patients receive timely and 
high-quality care. Although there is debate as to whether delays in treatment have 
any deleterious effects on survival, delays in treatment have been shown to have 
adverse effects on the psychological well-being of cancer patients (Montazeri et al., 
1998; Simunovic et al., 2001; Ristvedt & Trinkaus, 2005b; Lyckholm, 2006).  
This study demonstrated that the interdisciplinary pulmonary oncology 
service at the Jewish General Hospital actively treated a large proportion of its 
patients, including those with advanced lung cancer, within the waiting times 
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recommended by various agencies.  Eighty-seven percent of JGH patients received 
active treatment, comparable to the 70-87% rate reported by other interdisciplinary 
teams (Deegan et al., 1998; Fleissig et al., 2006; Newman et al., 2006). Furthermore, 
eighty-four percent of advanced stage patients received active treatment. Patients 
with SCLC had significantly shorter waiting times as compared to patients with 
NSCLC, as did patients first consulted in-hospital compared to those first consulted 
in the outpatient clinic.  
 There are two main organizational elements that may explain the success rate 
of the pulmonary oncology program: the weekly interdisciplinary meeting and the 
patient management model.  Although this study was not designed to measure the 
effect of interdisciplinary patient management on waiting times, the clinical context 
in which patients are seen should be noted.  The weekly interdisciplinary meeting 
allows team members to review and discuss all new and ongoing cases, which 
facilitates communication and may speed the referral process for diagnostic and 
treatment procedures.  Furthermore, discussion of challenging cases at a weekly 
meeting may lead to a faster diagnosis or treatment plan decision compared to 
sending the patient for a second opinion.  The patient management model ensures 
that a nurse-pulmonary oncologist team is responsible for the care of each patient. A 
nurse pivot is assigned to navigate each patient through the diagnostic and treatment 
process. Having a primary point of contact and a patient resource may reduce delays 
associated with patient follow-up and scheduling.  
Among the most commonly studied and most widely reported intervals is the 
interval from RTT to first treatment. This is an interval that should be easily 
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comparable across treatment facilities and provinces, since at this stage in the care 
trajectory all diagnostic tests have been completed and there should be minimal 
delays in initiating treatment. Delays at this stage would include managerial matters 
such as scheduling operating room time, planning for radiation therapy, scheduling 
chemotherapy or palliative radiation, or repeating outdated CT scans.  Palliative 
radiation and chemotherapy treatment require less planning and thus entail fewer 
administrative delays than more complex curative procedures.  
In the absence of comprehensive national recommendations for waiting times 
in cancer care, existing guidelines and benchmarks for RTT to treatment were 
achievable in the lung cancer population treated at the Jewish General Hospital. The 
interdisciplinary pulmonary service was particularly successful in meeting the 
Cancer Care Ontario guidelines for chemotherapy and surgery. The weakness of the 
interdisciplinary pulmonary service in relation to CCO guidelines was in the 
treatment interval for radiotherapy patients.  Less than 40% of radiotherapy patients 
started their treatment within the recommended waiting time. This may be a result of 
the high demand for radiotherapy services across many tumor sites, whereas the 
provision of chemotherapy and surgical services are more specialized according to 
diagnosis (Hunter, 2003; Rolke et al., 2007). High demand for radiotherapy services 
and consequent delays in treatment is not a recent problem in Québec. In fact, 
lengthy waiting times for radiation therapy were responsible for cancer patients in 
the Montreal region being transferred to facilities in the United States in the late 
1990s (Spurgeon, 1999).  
 In spite of its performance against the CCO guidelines, when compared 
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against the pan-Canadian benchmarks for radiotherapy, the interdisciplinary 
pulmonary service treats 90% of patients within the 28-day target. This discrepancy 
in the standards set for radiation treatment suggests that more work needs to be done 
to harmonize waiting time benchmarks in Canada. As more information on waiting 
times becomes available, more accurate and pragmatic benchmarks can be 
established (Wait Time Alliance for Timely Access to Health Care, 2007).  
The British Thoracic Society guidelines were a valuable assessment tool, as 
they are specific to the lung cancer population and they have been referenced in a 
variety of studies assessing lung cancer services. The interdisciplinary service 
performed well according to the BTS guidelines, although the 7 working day 
timeline for chemotherapy was the least successful of all of the treatment modalities 
in terms of percentage of patients treated within the target time.  
Although eighty-two percent of our patients over 65 years of age received 
active treatment, they were almost half as likely to be seen within the BTS 
guidelines than patients under 65. The results for patients over age 75 were not 
significant. There was no significant difference in performance status among 
patients over 65 as compared to their younger counterparts, nor was there a 
significant difference in treatment modalities for elderly patients. Consequently, the 
significant difference in waiting time and the significant number of elderly patients 
receiving supportive care points to a distressing tendency in the JGH’s pulmonary 
oncology service. The option not to undergo cytotoxic or physically demanding 
treatment may be a personal choice more often taken by elderly patients, but a bias 
toward longer delays cannot be excluded in our population. 
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There is limited evidence in the literature to suggest that elderly patients 
routinely wait longer for treatment. However, it is well documented that elderly 
patients are not well represented in clinical trials and are more likely to receive 
supportive care only (Gridelli, 2007).  There is some evidence to suggest that 
treatment and referral patterns also differ for elderly patients (Townsley, 2003). As 
cancer becomes increasingly a disease of the elderly, ensuring that older patients 
receive timely treatment is essential.   
There may, however, be legitimate reasons for the longer delay for elderly 
patients.  Hesitancy on the part of the physician, the patient, or the patient’s family 
may delay the commencement of therapy ("Focus group," June 19, 2008).  The risks 
to an older patient, notably in terms of toxicity, may be perceived to be greater, even 
in spite of a performance status that indicates suitability for treatment.  A 
comprehensive geriatric assessment may provide a more nuanced picture of an 
elderly patient’s ability to tolerate treatment (Extermann & Hurria, 2007).  It takes 
into account other factors such as cognition, social support, and nutritional status, 
that traditional measures of functional status do not.  Although this may add to the 
waiting time for elderly patients prior to their RTT date, it may avoid undue delays 
once a treatment decision has been made. 
The shorter delay for patients with more advanced stage and poorer 
performance status is consistent with earlier studies (Salomaa et al., 2005; Gould et 
al., 2008).  It was noted previously that patients with advanced stage are more likely 
to be symptomatic, therefore the need for rapid symptom palliation is greater. 
Furthermore, patients with earlier stage disease often have treatments that require 
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more complex planning, or are more difficult to stage, thus adding to the waiting 
time. Curative radiotherapy, for example, requires more complex planning than 
palliative radiotherapy, and surgical consultations prior to resection may lead to 
longer delays as compared to palliative radiotherapy or chemotherapy (Johnston et 
al., 2004; Salomaa et al., 2005). 
The shorter waiting time for the R-FT interval for patients with SCLC is also 
consistent with previous studies (Salomaa et al., 2005; Rolke et al., 2007). Given the 
responsiveness of SCLC to chemotherapy, it is standard practice to initiate SCLC as 
soon as possible (Rolke et al., 2007).  Furthermore, NSCLC patients are more likely 
to be referred to surgery or radiation therapy as a first-line treatment, which requires 
more planning and thus entails more administrative delays than administering 
chemotherapy to patients with extensive SCLC (Rolke et al., 2007).   
However, changes to the treatment standard for limited stage SCLC now 
require that these patients receive concurrent chemotherapy and radiotherapy 
(Socinski, 2007).  This may entail delays in initiating chemotherapy, as radiation 
requires more complex planning and scheduling. Given the importance of early 
initiation of chemotherapy and radiotherapy for the treatment of SCLC, this change 
in standard practice must be carefully monitored. Although early concurrent 
chemotherapy and radiation therapy (within the first 30 days of initiation of 
chemotherapy) is the treatment of choice for limited stage SCLC and stage IIIA 
NSCLC (Curran, 2006; Urbanic & Blackstock, 2006; Socinski, 2007), less than 45% 
of patients (9 of 22) received early radiation.  This suggests a lack of capacity to 
manage the demand for radiation therapy among lung cancer patients, and may be 
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resulting in suboptimal treatment among early-stage patients. 
 
Limitations  
Both the BTS and CCO guidelines contain waiting time recommendations 
for the interval from family doctor referral to first consultation with a specialist. This 
information was not available for the study period. Until recently, referral data was 
not systematically collected in the department.  However, as a result of this audit, 
more detailed information on referral path and dates are being collected and stored 
in our database. Better data reporting mechanisms are being implemented within the 
pulmonary oncology program that will facilitate performance audits.  Information 
that is of particular interest for future prospective audits includes better data on the 
referral source and length of time from referral to first visit, the number of 
diagnostic procedures completed before tissue diagnosis is achieved, and the number 
of clinical studies enrolled in by each patient.  
 The retrospective design of this study did not provide details on the workup 
of patients prior to their diagnosis or treatment. For instance, a patient with 
suspected SCLC ultimately diagnosed with NSCLC may have had a shorter clinical 
trajectory given the higher priority for patients with SCLC. More detailed 
information on the suspected diagnosis or the planned treatment prior to staging 
would provide a more accurate picture of waiting times, given the changes to 
treatment plans over the course of the workup. A prospective approach would permit 
the collection and evaluation of this data. 
This study was not designed to assess the role that the interdisciplinary team 
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played in the management of waiting times. However, the interdisciplinary team at 
the JGH may have played an important role in reducing referral delays among 
specialists, improving communication among specialists and between team members 
and patients, and in creating a treatment plan.  Indeed, other groups have reported 
that interdisciplinary team management leads to improved communication and 
reduces referral delays among specialists (Deegan et al., 1998; Fleissig et al., 2006; 
Newman et al., 2006).  The maintenance of a database has also been integral to our 
clinical service as it enables review for quality control purposes.  
An important limitation of this study was in attempting to harmonize the 
experience of over 400 patients.  Not all patients follow the same clinical trajectory, 
and attempting to create indicators that are representative of a large heterogeneous 
group was challenging.  Consequently, the assessment of treatment intervals was 
complex.  There were numerous patients with negative intervals that were excluded 
from analyses since their trajectory did not match the standard clinical picture.  This 
reinforces the utility of the ready-to-treat to treatment interval, since at that point all 
investigations have been completed and the patient is simply waiting for treatment.  
 Finally, since this study examines the quality of clinical services at a single 
centre, its external validity is limited.  However, the time intervals employed for the 
analysis, particularly the R-FT interval, were designed to be comparable to 
provincial, national and international guidelines.  As such, the waiting times 
achieved at the JGH can be compared to the waiting times at any other hospital in 
Quebec or across Canada, provided that the other sites are using the same reporting 
criteria. Moreover, this study may prove useful to other sites by describing a model 
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of interdisciplinary management, and by highlighting both the successes and areas of 
improvement for the pulmonary oncology program. 
 
Recommendations 
Efforts must be made to ensure that patients receiving concurrent Day 1 
chemotherapy and radiation therapy are planned and scheduled with minimal delays.  
Given the impact of early initiation of concurrent treatment on survival (Socinski, 
2007), the timing of treatment is of utmost importance. Given the discrepancy in 
median waiting times for chemotherapy versus radiotherapy, the limiting factor for 
concurrent treatment is radiation therapy planning.  Ensuring timely treatment for 
these patients may require additional resources both in terms of equipment and 
health professionals. 
Elderly patients must receive the same timely treatment as their younger 
counterparts.  Given that the waiting time experience of elderly patients cannot be 
explained by performance status or treatment modality, it is essential to address the 
treatment time discrepancy among elderly patients. It may be that there is some 
hesitancy on the part of physicians to offer treatment to elderly patients, even in 
spite of good performance status. A comprehensive geriatric assessment (CGA) may 
provide a more nuanced picture of an elderly patient’s ability to tolerate treatment 
(Extermann & Hurria, 2007). Although this may add to the waiting time for elderly 
patients prior to their RTT date, it may avoid undue delays once a treatment decision 
has been made. This practice has already been adopted by the pulmonary oncology 
service at the JGH.   
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The guidelines examined in this study consider only the earliest and latest 
stages of a patient’s trajectory, recommending waiting times from referral to a 
specialist to diagnosis, and then from RTT to treatment.  However, considerable 
attention should be paid to the period between diagnosis and RTT.  This period is 
composed of elements including staging, scheduling, and treatment planning. 
Considering the importance of these elements to a patient’s overall clinical 
trajectory, efforts should be made to reduce this interval, even in (or perhaps because 
of) the absence of specific waiting time recommendations. 
The value of consistent, standardized waiting time indicators and guidelines 
for cancer treatment in Canada cannot be overemphasized. Although there are 
challenges inherent in the collection and analysis of waiting times data across the 
country, consistent indicators and goals are a necessity. Collaboration of provincial 
cancer agencies and other groups may facilitate the development of useful waiting 
time indicators and benchmarks, which will provide regional cancer centres and 
smaller institutions with a single standard against which to measure the quality of 
their care.    
 
Conclusions 
 The assessment of the clinical performance of the interdisciplinary 
pulmonary oncology program at the Jewish General Hospital identified several 
strengths and weaknesses. A large proportion of patients undergoing chemotherapy 
and surgery are seen within recommended waiting times. There were weaknesses in 
achieving recommended waiting times for radiation therapy, as well as weaknesses 
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in treating elderly patients, patients with early-stage disease and patients with good 
performance status within recommended guidelines. Future audits should be 
prospective and provide more detailed information on referral patterns and 
diagnostic testing.  Any reductions in waiting times should be balanced against the 
need for thorough investigation and staging of each patient prior to initiating 
treatment.  
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Figure 1: Clinical intervals in the treatment trajectory of lung cancer patients 
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Table 1: Patient characteristics 
 Frequency 
(N=473) 
Percent  
(%) 
Year of Diagnosis 
         2004 
         2005 
         2006 
         2007 
 
104 
141 
129 
99 
 
22 
30 
27 
21 
Male 
Female 
245 
228 
52 
48 
Age (years) 
       < 65 
        65-75 
       > 75 
 
193  
155 
113 
 
42 
34 
24 
Smoking Status 
         Smoker  
        Ex-smoker  
       Never-smoker 
      Missing data 
 
162 
229 
63 
19 
 
50 
36 
14 
Diagnosis 
         NSCLC 
         SCLC 
 
427 
46 
 
90 
10 
NSCLC Subtype 
         Adenocarcinoma 
         Squamous carcinoma 
         Undifferentiated 
         Bronchoalveolar carcinoma 
         Large cell 
         Mixed 
 
226 
72 
53 
41 
32 
3 
 
53 
17 
12 
10 
7 
1 
NSCLC Stage  
         IA-IB 
          IIA-IIB 
          IIIA 
          IIIB 
          IIIB pleural effusion 
          IV 
SCLC Stage 
          LTD 
          EXT 
Missing data 
 
71 
32 
36 
48 
33 
203 
 
8 
35 
7  
 
17 
7 
9 
11 
8 
48 
 
19 
81 
Proximity to hospital 
        Within 20km 
         21-50km 
         51-100km 
         > 100km 
 
379 
70 
15 
9 
 
80 
15 
3 
2 
First consult with pulmonary physician 
         Outpatient referral from GP or    
specialist 
 In-patient consult    
Referral from Emergency Department 
Missing data 
 
336 
 
92 
25 
8 
 
74 
 
20 
5 
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Table 2: First Treatment  
Frequency 
(n=461) 
 
 
NSCLC SCLC 
Treatment priority level 
       II 
     III 
 
80 
278 
 
43 
0 
Chemotherapy 
      Double Agent  
      Single Agent  
     TKI  
111 
74 
22 
15 
37 
37 
0 
0 
Radiotherapy 
     Palliative  
     Curative 
94 
80 
14 
4 
4 
 
Concurrent chemo-
radiotherapy 
 
20 
 
2 
Sequential chemo-
radiotherapy 
 
12 
 
0 
Thoracic surgery  
 
114 0 
Other surgery (resection of 
brain metastasis, 
stabilization of spine, etc.) 
7 0 
Supportive care 59 1 
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Table 3: Adherence to CCO, BTS and pan-Canadian waiting time guidelines  
Interval R-FT 
(Ready to treat to 
first treatment) 
(n=371) 
Target JGH Median 
(days) 
JGH 
Mean 
(days) 
% JGH 
patients 
within target 
(n) 
 
Cancer Care Ontario 
(days) 
   
Chemotherapy 
      Priority II 
     Priority III 
Radiation therapy 
      Priority II 
     Priority III 
Surgery 
     Priority II 
     Priority III 
 
7 
14 
 
7 
14 
 
14 
28 
 
5 
9 
 
9 
22 
 
 
10 
 
5 
11 
 
11.5 
25 
 
 
14 
 
81 (36) 
71 (129) 
 
32 (81) 
33 (22) 
 
 
91 (100) 
 
British Thoracic 
Society 
(days) 
   
Chemotherapy 
Radiation therapy 
      Palliative 
     Radical 
Surgery 
7 working 
 
14 
28 
28 
8 
 
9 
22 
10 
9.5 
 
11.5 
25 
14 
69 (165) 
 
73 (81) 
71 (22) 
91 (100) 
 
pan-Canadian 
Benchmarks for 
Radiation Therapy 
(days) 
   
 
28 11.5 14 90 (n=96) 
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Table 4: Crude and adjusted Odds Ratios of being seen within BTS-
recommended waiting time intervals 
 
N= 371 ORcrude (95% CI) 
 
ORajusted (95% CI)  
Age 
<65 
65-75 
>75 
 
1.00* 
0.67 (0.40-1.11) 
0.54 (0.30-0.97) 
 
1.00* 
0.53 (0.30-0.94) 
0.55 (0.28-1.10)  
Stage 
IA-IIIA, LTD 
IIIB-IV, EXT 
 
0.37 (0.22-0.60) 
1.00* 
 
0.52 (0.29-0.95)  
1.00* 
Diagnosis 
SCLC  
NSCLC 
 
1.83 (0.82-4.20)  
1.00* 
 
2.95 (1.20-7.28) 
1.00* 
ECOG Performance Status 
0-1 
2-3 
 
1.33 (0.74-2.37) 
1.00* 
 
0.48 (0.25-0.91) 
1.00* 
First consult 
Pulmonary oncology clinic 
Emergency Department 
In-hospital 
 
1.14 (0.63-2.06) 
0.77 (0.28-2.17) 
1.00* 
 
0.97 (0.49-1.95) 
0.88 (0.27-2.91) 
1.00* 
First treatment 
Chemotherapy 
Radiation 
Surgery  
 
0.20 (0.09-0.41) 
0.14 (0.07-0.30) 
1.00* 
 
0.23 (0.10-0.56) 
0.16 (0.07-0.39) 
1.00* 
* reference category 
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Figure 2.  Intervals FC-D and R-FT 
 
Ready to treat to date of first treatmentTime between first consult with pulmonary to 
diagnosis
100
80
60
40
20
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
90 
Figure 3.  Intervals D-FT and FC-FT 
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DISCUSSION          
 
Analysis of waiting time intervals and comparison with published studies 
The overall median waiting time from first consultation with the pulmonary 
service and initiation of treatment was 30 days in this study.  In previous lung cancer 
studies this interval was between 25 days and 49 days (Myrdal et al., 2004; Salomaa 
et al., 2005; Rolke et al., 2007).  This situates the waiting times at the JGH at the 
lower end of waiting times among published reports.  
To date there have been no published studies assessing clinical performance 
against Cancer Care Ontario waiting time guidelines, or against the pan-Canadian 
guidelines for radiation therapy.  However, Ontario institutions have published their 
waiting time results online and provinces and territories have begun reporting on 
waiting time indicators in various regions (Cancer Care Ontario, 2008; Ontario 
Ministry of Health and Long-Term Care, 2008).  In Québec, online reports indicate 
that over 80% of patients in the Montreal region are receiving radiation therapy 
within 28 days of being ready to treat.  However, it is unclear how recent these data 
are and how they have been collected (Ministère de la santé et des services sociaux 
du Québec, 2008).   
Winget (2007) examined the performance of cancer clinics in Alberta, 
Saskatchewan and Manitoba in relation to waiting time intervals agreed upon by the 
provinces’ cancer agencies. The median waiting time from diagnosis to first 
radiation or chemotherapy treatment for lung cancer patients achieved by Alberta, 
Saskatchewan and Manitoba was 31, 41 and 36 days, respectively. The median 
waiting time for patients at the JGH for this same interval was 25 days.  The 
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definitions used by Winget for date of diagnosis and date of first treatment are 
consistent with the definitions used in this study, and therefore these intervals are 
comparable.  Although the waiting time at the JGH is shorter than the reported 
waiting times in the three provinces, the scale of these studies varies considerably 
and the provincial data are aggregates of all of the cancer centres in the province, 
whereas the JGH data represent waiting times at a single centre.  However, creating 
comparable indicators and intervals against which to assess clinical performance is 
the first step in informing policy on quality of care for cancer (Winget et al., 2007). 
The British Thoracic Society guidelines applied in Section 4 have been used 
as a comparative tool in a number of studies.  Several international papers have 
compared the activities in their lung cancer clinics to recommendations from the 
BTS (Deegan et al., 1998; Riedel, Wang, McCormack, Toloza, Montana et al., 2006; 
Rolke et al., 2007).   
Deegan (1998) assessed the BTS recommendation of patients receiving a 
firm diagnosis within 2 weeks of first being seen in his study cohort. In our 
population the median time from first consultation to diagnosis was 14 days.  Fifty-
eight percent of patients had a diagnostic procedure performed within 2 weeks of 
first being seen by a pulmonary specialist.  In Deegan’s cohort, 77% of patients 
received a diagnosis within 2 weeks of being seen. Deegan’s cohort received a 
diagnosis in a more timely manner than the JGH population, although the size of the 
group being examined (n=81) was much smaller than the JGH’s (n=340) and over a 
shorter time period (five months vs. four years). The waiting times of the JGH 
population for this interval may in fact be longer, since the date of diagnosis listed in 
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the database is the date that the procedure was performed, rather than the date it was 
reported or the date the patient received the diagnosis.  
Riedel (2006) retrospectively compared the outcome measures of a 
multidisciplinary thoracic oncology clinic (MTOC) to those of a non-MTOC at the 
same institution.  The study examined two time periods, from first visit to any 
physician to date of diagnosis, and from date of diagnosis to initiation of treatment. 
The time from first visit to diagnosis in Riedel’s study was 47 days (n=164) and 48 
(n=89) days for MTOC and non-MTOC patients, respectively.  In the JGH 
population, the time from first visit to diagnosis was 14 days (n=340). However, the 
definition of first visit in Riedel’s study is the first visit to any physician for a 
cancer-related sign or symptom.  Since the JGH data defines the first consult as the 
first contact with a pulmonary physician, this interval may be artificially short as 
compared to Riedel’s cohort.  The second interval, however, from diagnosis to first 
treatment, was measured using the same criteria in both studies.  In Riedel’s cohort, 
the median time from diagnosis to first treatment was 21 days (n=205) for MTOC 
patients and 23 days (n=89) for non-MTOC patients.  In the JGH population, this 
interval was 25 days (n=297).  Riedel concluded that since there was no significant 
statistical difference in the timeliness of care for MTOC patients versus non-MTOC 
patients, multidisciplinary clinics could not be said to affect the timeliness of care. 
However, Riedel’s study examined the MTOC clinic prior to the non-MTOC clinic. 
Some of the infrastructure in place for the MTOC clinic, including a database and 
weekly multidisciplinary conferences, were maintained following the dissolution of 
the MTOC clinic.  Riedel points to the maintenance of the weekly multidisciplinary 
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conference as a significant flaw in the methodology and subsequent conclusions that 
can be drawn from his study. Indeed, the continuing use of the weekly 
multidisciplinary conferences is an important limitation to his study and the 
classification of the second clinic as non-MTOC may be misleading, as it retains a 
key feature of multidisciplinary management.  
 Rolke (2007) assessed the performance of her Norwegian study cohort 
against the recommendations of the BTS and the Swedish Lung Cancer Study 
Group.  She examined a number of intervals from the first symptom through to the 
first treatment. Intervals from Rolke’s study which are comparable to the JGH 
population include the “specialist delay” from first contact with pulmonary 
consultant to dated diagnostic histology/cytology, and “hospital delay”, from first 
contact with pulmonary consultant to first treatment.  In Rolke’s study, the specialist 
delay was a median of 8 days (n=448), whereas in the JGH population the delay was 
14 days.  The hospital delay in Rolke’s population was a median of 25 days (n=310), 
whereas in the JGH population the hospital delay was 30 days (n=357). Although 
neither of those intervals is the subject of BTS recommendations, the overall 
hospital delay was the subject of the Swedish Lung Cancer Study Group’s 
recommendations.  They suggested that 80% of patients have a hospital delay of no 
more than 31 days.  In Rolke’s study, 62% of patients had a hospital delay of 31 
days or less.  In the JGH population, 51% of patients had a hospital delay of 31 days 
or less.   
 The waiting times in the clinical trajectory of patients at the JGH are keeping 
pace with reported waiting times in the international literature.  While the JGH 
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waiting times lag behind for certain intervals, namely the period between first 
consultation and diagnosis, the median waiting time for the entire clinical trajectory 
is similar to other studies (Salomaa et al., 2005).  Furthermore, between 60 and 90% 
of patients seen in the pulmonary service are receiving treatment within the BTS 
waiting time recommendations (see Section 4). 
  
Critical pathways 
 
Critical pathways are management tools used in hospital settings that set out 
timelines and sequences of events in a patient’s clinical trajectory.  Patients are 
assigned to critical pathways for a variety of medical procedures, particularly cardiac 
care and surgery (Pearson et al., 1995; Every et al., 2000; Smith & Hillner, 2001). 
Critical pathways are not presently employed as a clinical tool for the treatment of 
lung cancer patients at the Jewish General Hospital.  For the purposes of this study, 
however, the critical pathways technique is used conceptually in order to identify the 
longest interval in a patient’s trajectory, and thus to identify the interval that 
contributes most to the patient’s overall waiting time.   
According to results, the critical pathway for this study is the interval 
between first consultation with a pulmonary specialist and diagnosis, with an overall 
median of 14 days. This result is consistent with other studies, which have identified 
the first interval between consultation and diagnosis to be the lengthiest. 
Devbhandari (2007) has suggested that the longest delay occurs in the diagnosis and 
staging work-up period. A negative initial bronchoscopy, for example, requires that 
patients have further investigations in order to achieve a diagnosis. While this 
increase in the time to diagnosis is not necessarily the result of administrative or 
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managerial delays, but the result of a more complicated or challenging case, re-
scheduling and re-performing bronchoscopy or other diagnostic procedures will 
nonetheless contribute to the overall waiting time. Although this study did not 
examine detailed information on the number of diagnostic tests or staging studies, 
delays resulting from repeated diagnostic procedures have been identified in 
previous studies (Devbhandari, Bittar et al., 2007; Devbhandari, Soon et al., 2007), 
and it is a plausible explanation for the waiting time in this interval at the Jewish 
General Hospital.  Future prospective audits should consider this question in more 
detail. 
 Given the number of exclusions due to negative intervals in the study, and 
the subsequent reduction in n for the calculation of mean and median waiting times, 
it is clear that patients follow a variety of paths throughout their treatment trajectory.  
Every (2000) identifies this limitation by suggesting that the critical pathways 
approach examines the ideal patient rather than the experience of actual patients.  
Similarly, this study used an ideal patient approach by creating intervals based on a 
common trajectory, but one that does not represent the experience of all patients.  
Consequently, the utility of critical pathways as a conceptual tool, rather than a 
clinical one, is somewhat mitigated. This should not lead to the conclusion that 
treatment intervals must not be examined to seek improvements; rather, it is 
recognizing that a critical pathways approach may not be successful when clinical 
trajectories vary widely.   
Alternatively, as Every (2000) concludes, critical pathways can serve as a 
screening test for inefficient care. In spite of the limitations of creating a single path 
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for assessing waiting time intervals, the critical pathways conceptual approach did 
allow for the identification of the rate-limiting step in the clinical trajectory of lung 
cancer patients.  A next step for the pulmonary oncology service at the JGH may be 
to institute a clinical pilot of the critical pathways approach for one type of 
treatment, which may improve efficiency and decrease the median waiting time for 
that treatment modality.  
 Considering the challenges inherent in the critical pathways approach 
explored above, a more useful exercise for cancer care may be to examine the 
experience of patient subgroups. For instance, identifying and repairing the 
systematic disparate treatment of elderly patients may have as great an impact on 
clinical services as identifying a rate-limiting interval.  Investigating the roots of this 
unequal treatment will require additional analysis and discussion among 
interdisciplinary team members in order to develop appropriate solutions.  However, 
the exercise of identifying inefficiencies and systematic waiting time variations has 
been a valuable first step. 
De Vries (2007) and colleagues are developing a critical pathways approach 
specific to elderly patients, which will maintain a patient-specific implementation 
procedure along with a particular focus on geriatric issues such as polypharmacy, 
co-morbidities and cognitive status.  This approach may prove to be valuable in 
reducing waiting times for elderly patients as compared to their younger 
counterparts. As discussed in Section 4, the implementation of the geriatric 
assessment for patients over age 70 at the Jewish General Hospital may also assist in 
reducing the waiting time between ready-to-treat and first treatment. This 
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assessment has been in place for the lung cancer population since early 2007.  A 
future audit could examine differences in waiting times for elderly patients prior to 
the introduction of the geriatric assessment versus waiting times following its 
introduction. 
The detection of other systematic discrepancies among subgroups in the JGH 
population was more predictable, and for the most part not cause for a re-evaluation 
of clinical services.  For instance, that SCLC patients should be treated in a timelier 
manner than NSCLC patients is expected and reassuring.  Given that SCLC is more 
aggressive and more responsive to treatment, even a suspicion of SCLC prior to a 
tissue diagnosis merits a more rapid diagnostic and staging trajectory.   
 
Waiting time intervals and the pertinence of guidelines 
In assessing the performance of the pulmonary oncology program at the JGH 
against existing guidelines from Canada and beyond, there are two elements that 
merit further exploration: the lack of recommendations on waiting times for the 
middle stages of the patient’s clinical trajectory, and the variation in waiting time 
recommendations that exists among the guidelines.   
The two sets of comprehensive guidelines from the BTS and the CCO both 
make recommendations for the early stages of care, from referral to consultation 
with a specialist, and in the case of BTS, from consultation to diagnosis. They also 
make recommendations for the final stage of the trajectory, from ready to treat to 
initiation of treatment (see Figure 1 in Section 4 and Annex 1a for reference).  The 
intermediate intervals, variously involving diagnosis, staging, and the creation of a 
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treatment plan, are not the subject of either organization’s recommendations.   
Given the challenges explored above in relation to critical pathways and the 
exclusion of patients with negative intervals, perhaps the omission of these intervals 
in the waiting time guidelines are an implicit recognition of the variation in a 
patient’s care path. Although it is possible only to speculate as to why these 
intermediate intervals were not included in the expert recommendations on waiting 
times, it may be that the experts encountered difficulty defining waiting intervals for 
such a heterogeneous patient experience, taking into account delays in diagnostic 
imaging, scheduling of appointments, and planning treatment. However, omitting 
these intervals from recommendations risks allowing excessive variation in a 
patient’s waiting time, since the only intervals under scrutiny occur at the beginning 
and the end of a patient’s course.  It would be valuable to have an overall “hospital 
delay” interval, such as the one proposed by the SLCSG (Myrdal et al., 2004), in 
order to define the optimal length of the entire clinical trajectory.   
The guidelines used in this study to assess the performance of the pulmonary 
oncology program differ from one another, and, consequently, the performance of 
the pulmonary oncology program varies according to the various sets of 
recommendations. Most notably, the radiotherapy guidelines from the three different 
sources provide vastly different pictures of the performance of the pulmonary 
oncology service.  According to the Cancer Care Ontario guidelines, thirty-two and 
thirty-three percent of palliative radiotherapy and curative radiotherapy patients, 
respectively, achieved the benchmark waiting times.  When assessed against the 
British Thoracic Society guidelines, however, seventy-three and seventy-one percent 
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of those same palliative and curative patients, respectively, met the guidelines. When 
compared against the pan-Canadian guidelines, ninety percent of radiation therapy 
patients met the benchmark of 28 days from ready to treat to treatment.   
How to explain the variation in the target times recommended by these 
different organizations? A focus group of clinicians at the Jewish General Hospital 
were asked their opinion on the value of the various benchmarks used in this study.  
The group concluded that the Cancer Care Ontario guidelines were overly general to 
apply to the lung cancer population, and therefore the guidelines were not perceived 
as particularly useful. The British Thoracic Society guidelines, however, were met 
with support. They were sufficiently specific to be useful, and they also reflected 
achievable targets for the pulmonary oncology service. The pan-Canadian guidelines 
were perceived as too lenient, even in light of the demands on the radiation oncology 
department from other tumor sites.  The clinicians felt that a maximum waiting time 
of ten days to two weeks was ideal for both palliative and curative radiotherapy 
("Focus group," June 19, 2008).   
Indeed, the pan-Canadian benchmarks for radiation therapy have already 
been criticized by the Wait Time Alliance for being overly relaxed (Wait Time 
Alliance for Timely Access to Health Care, 2007).  However, as described by the 
WTA, waiting time recommendations are fluid, especially in this seminal period of 
benchmark development. As data become more readily available and accessible, 
waiting time benchmarks will adjust accordingly (Wait Time Alliance for Timely 
Access to Health Care, 2007). 
Given the variation in the recommended times for various treatments 
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suggested by the different organizations, and given that the Canadian government 
has not yet established comprehensive guidelines for cancer treatment, the next 
question is, what should be informing waiting time benchmark development in 
Canada? Is there an advantage to national clinical benchmarks? Currently, provinces 
are working independently to establish their own sets of indicators and benchmarks.  
As a result, indicators are not uniform across the country and therefore are difficult 
to compare against one another (Wait Time Alliance for Timely Access to Health 
Care, 2005; Canadian Institute for Health Information, 2006; Canadian Breast 
Cancer Network, 2008).  
Furthermore, the design of benchmarks is piecemeal and the potential exists 
for waiting time standards to vary from province to province. It is important to 
ensure that the benchmarks being established are consistent across the country, while 
still considering the realities of resource allocation and capacity. Benchmarks must 
be consistent across the country in order to ensure that patients are receiving the 
same standard of care regardless of their province of residence. In order to achieve 
consistent benchmarks, indicators for waiting times must also be consistent.  As 
Winget (2007) explains: 
[…] production of standardized “wait-time” data across 
Canadian provinces will allow identification at the national 
level of problems which facilitate solutions and changes to 
current resource allocation and overall system improvements. 
 
Not only will standardized waiting time indicators allow identification of problems, 
they are vital to informing policy makers in the creation of suitable benchmarks.  
Strengths and weaknesses in waiting time intervals can be identified, and best 
practices can be shared among provinces (Winget et al., 2007). 
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Assessing the performance of the JGH’s pulmonary oncology service against 
the various guidelines also raises the question of whether unique benchmarks for 
various types of cancers should be developed, or whether all cancers should have the 
same set of benchmarks. According to the clinicians at the JGH, the guidelines 
established by the BTS are more useful than the generalized recommendations made 
by the CCO ("Focus group," June 19, 2008). In any case, considering the challenges 
inherent in establishing waiting time guidelines for cancer care, it is likely that 
general guidelines will precede specialized ones until enough evidence has been 
accumulated to be sufficiently specific.   
A recent report from the Canadian Breast Cancer Network (2008) highlights 
the difficulties in reducing waiting times in cancer care in Canada.  The report, 
issued in January 2008, addresses some of the key factors that hinder the creation of 
waiting time benchmarks and the ensuing reduction in waiting times, with specific 
reference to the experience of breast cancer patients.  Many of the factors identified 
by the CBCN, however, are the same challenges facing the lung cancer community.   
For example, the CBCN identifies lacunae in the data reporting and a 
shortage of comparable measures on waiting times among the provinces and 
territories.  This has also been identified in earlier reports by CIHI (2006) and the 
WTA (2005, 2007); however, the CBCN points out that as of 2008 it remains an 
issue and is limiting the advancement of knowledge with respect to waiting times in 
Canada.  Furthermore, the report suggests that Canada lags behind with respect to 
the use of electronic medical records, limiting the speed and accuracy with which 
information can be disseminated. The report also highlights the lack of national 
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clinical benchmarks for breast cancer chemotherapy and surgery, an issue that is not 
limited to the breast cancer population.  Finally, the report points to a shortage of 
health human resources and equipment, which affects the capacity to treat patients in 
a timely manner. All of these issues extend beyond the scope of breast cancer 
treatment and represent obstacles to the creation of waiting time guidelines and the 
subsequent reduction of waiting times for cancer care on a wider scale.   
 
LIMITATIONS OF THE STUDY       
Some of the limitations of this study have been explored in the article 
entitled Waiting times in the clinical trajectory of patients with lung cancer (refer to 
Section 4). Among the limitations of this study was the retrospective design of the 
study.  Consequently, some information of interest was not available for analysis.  In 
particular, the interval from the referral to first consultation with pulmonary was not 
available, nor were the number of diagnostic procedures necessary in order to obtain 
a tissue diagnosis for each patient.  Furthermore, when comparing the pulmonary 
service against Cancer Care Ontario guidelines, proxies were created to establish 
indicators comparable to the priority system used by the CCO.  Since this was done 
post-hoc, rather than a priori as recommended by the guidelines, the proxies were 
not entirely comparable to the CCO’s priority system.   
The primary limitation of this study is the reduction in n as a result of the 
exclusion of patients achieving negative intervals. The trajectory from first 
consultation to first treatment is representative of a typical patient; however, there 
are deviations from this trajectory so that for each of the intervals examined, a large 
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number of patients were excluded based on negative intervals. Although there will 
always be individuals who do not meet the target time for any number of reasons, 
and though the CCO guidelines acknowledge this reality by suggesting that 90% of 
patients should meet the benchmark, excluding patients achieving negative intervals 
reduces the aggregate used to calculate mean and median times.  Consequently, this 
limits the strength of the conclusions that can be drawn regarding the performance of 
the pulmonary service.  Fortunately, the cohort of patients seen over the four-year 
study period is large enough to mitigate this weakness somewhat. 
Finally, this study is not designed to assess the impact of interdisciplinary 
teams on waiting times. Ideally, data would have been available prior to the 
institution of the interdisciplinary team in order to use a before-and-after model to 
assess performance in relation to waiting times. It is not possible using retrospective 
data to claim that the interdisciplinary team contributes to the waiting times achieved 
in this study population.  However, the design of this study is similar to other 
published reports assessing waiting times in lung cancer achieved by an 
interdisciplinary team.  These studies concluded that although they could not draw a 
conclusive link between interdisciplinary management and the waiting times 
achieved in the study, the interdisciplinary context in which the study took place was 
a contributing factor (Deegan et al., 1998; Conron et al., 2007; Devbhandari, Bittar 
et al., 2007; Rolke et al., 2007).  Similar to these studies, the interdisciplinary 
environment at the JGH is part of the context in which this study took place.   
Furthermore, based on studies that have assessed waiting times in breast cancer 
patients and shown positive effects, there are some features linked to the success of 
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those clinics that are present in the pulmonary oncology service at the Jewish 
General Hospital.  
Gabel and colleagues (1997) reported a significant reduction in the waiting 
time between diagnosis and treatment for patients seen in a multidisciplinary clinic.  
The features that characterized their multidisciplinary clinic were a cancer 
conference attended by a number of specialists involved in the diagnosis and 
treatment of breast cancer patients, wherein each case was reviewed radiologically 
and pathologically, and treatment options were discussed among all specialists.  The 
MDC also included an educational component for patients and a same-day, one-stop 
clinic where patients were seen by the consultants present at the earlier 
multidisciplinary meeting.   
Newman and colleagues (2006) describe changes to the management 
decisions of patients seen in second opinion by a multidisciplinary breast cancer 
conference.  After review by specialists in surgery, pathology, and radiology, more 
than half of patients had changes made to their surgical treatment plan based on the 
interpretation of radiographic, pathologic, and/or clinical findings.   
 Much like the MDCs described by Gabel (1997) and Newman (2006), the 
pulmonary oncology program at the JGH relies on an interdisciplinary cancer 
conference to discuss all suspected cases of lung cancer and decide on a treatment 
plan for each patient.  In fact, the ICC at the Jewish General Hospital has been 
presented by Cancer Care Ontario as a model for Ontario health care centres for the 
development and management of an interdisciplinary meeting (Hunter, 2006).  
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CONTRIBUTION TO THE BODY OF KNOWLEDGE  
  
 The momentum surrounding waiting times in Canada has been growing in 
the last five to ten years.  Influential documents such as the Romanow Commission’s 
Report on the Future of Health Care in Canada (2002) and the Supreme Court of 
Canada’s decision on Chaoulli v. Québec (Attorney General)3 have led the issue of 
waiting times in the Canadian health care system to take on new meaning. They 
created a stronger impetus to identify current practices and set benchmarks for the 
future, assisted in large part by public attention to the issue. Waiting times are 
particularly vital to cancer care, given the potentially life-threatening nature of the 
disease and the prevalence of various types of cancer in the population.   
 This study defines and situates the experience of patients at a single centre, in 
a teaching institution, in a major Canadian city. While this may limit its applicability 
in other contexts, it does provide a snapshot of clinical services in an 
interdisciplinary environment in a typical hospital in a large urban setting.  In that 
respect, the lessons learned from the examination of waiting times and treatment 
intervals can be of use to similar institutions, and in some instances, it can provide a 
warning bell for hospitals across Canada.  Particularly with respect to the treatment 
of elderly patients and radiotherapy waiting times, it is the responsibility of 
clinicians to assess whether a similar phenomenon is taking place in their healthcare 
setting.   
In terms of assessing the adequacy of waiting times against benchmarks, the 
experience of the patients at the JGH is now situated with respect to international, 
                                                 
3
 2005 SCC 35 
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pan-Canadian and provincial guidelines.  This is important as it helps the drafters of 
guidelines to determine what is realistic and achievable. In Québec, the provincial 
government has only recently started collecting information on radiation waiting 
times.  According to the government website, a future goal is to have all patients 
requiring oncological surgery to be treated within 4 weeks of ready to treat.  The 
slow progress towards reporting current practices and in establishing waiting time 
goals belies the importance of the issue in Québec and in Canada.  Having concrete 
and detailed evidence of current practices, even in a single setting, is a step towards 
better reporting and more realistic goals for waiting times in cancer care.  
Most provinces and territories have started reporting on particular intervals 
of their cancer treatment waiting times, but critics have remarked that each province 
is starting the clock at a different point along the care trajectory (Canadian Institute 
for Health Information, 2006; Kondro, 2006).  This makes the comparison of 
waiting times across Canada difficult.  One of the goals in this study was to create 
indicators that are readily comparable with guidelines and, ultimately, with 
provincial performance indicators. Accordingly, the performance of the pulmonary 
oncology service is now situated in relation to radiation oncology benchmarks across 
the country.  However, progress still must be made in order to achieve a clear picture 
of the status of waiting times for cancer care across Canada.   
 
RECOMMENDATIONS TO THE JEWISH GENERAL 
HOSPITAL 
The audit of clinical performance with respect to waiting times has generated 
a number of recommendations for the pulmonary oncology service. These 
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recommendations cover areas including radiation treatment, geriatric care, clinical 
management, and data collection. The recommendations concerning radiation 
therapy treatment and management of elderly patients have been articulated in 
Section 4; please refer to page 71.   
Future audits should be conducted prospectively. This will ensure that the 
information of interest is systematically collected and other areas of interest can be 
identified before beginning the audit. For example, patient satisfaction information 
can be collected, along with referral dates and dates of first symptoms, visits to the 
family physician, and so on.  A smaller but more thorough audit in the future would 
reveal if progress has been made on key areas identified in this study, for example 
the treatment of elderly patients, and could also provide insight into areas that were 
not available for this study.   
The use of critical pathways as a clinical tool may assist in the reduction of 
waiting times for certain key intervals in a patient’s trajectory.  To assess their utility 
to the pulmonary oncology program, critical pathways could be introduced as a 3-
month pilot project for the interval between first consultation and diagnosis for 
patients first seen in the pulmonary oncology clinic.  As the longest interval 
identified in this study and the subject of an existing waiting time recommendation, 
this interval is a suitable focus for potential waiting time reduction.  Given the 
positive response of the focus group to the BTS recommendations, the two-week 
waiting period could be used as a benchmark.  Both the date of the procedure and 
the date the patient is apprised of the result should be recorded. Results from this 
study could be compared to the critical pathways results to ascertain whether the 
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critical pathway tool is providing meaningful reductions in waiting times for that 
interval.    
Previous studies have reported on the value of a multidisciplinary clinic that 
combines the services of a number of specialists in one location. This minimizes the 
number of hospital visits for patients and reduces the waiting time between specialist 
visits (Deegan et al., 1998; Conron et al., 2007).  This is not currently the practice of 
the pulmonary oncology program at the Jewish General Hospital.  It may be an 
option for a redesign of the current pulmonary clinics, to exist in complement to the 
weekly interdisciplinary meeting.  This one-stop clinic may assist in further reducing 
waiting times among pulmonary oncology patients.   
 
AREAS OF FURTHER STUDY       
This study has focused on the interval from first contact to first treatment, as 
well as intermediate intervals that comprise the total hospital delay.  However, there 
are several other intervals that also require attention: the patient delay and the 
intervals following the initiation of a patient’s treatment.  
The patient delay is described as the time from first symptom to first contact 
with a pulmonary specialist (Moody et al., 2004).  This includes intervals such as 
first symptom to first visit with a general practitioner, from general practitioner to 
referral to specialist, and from referral to specialist to first seen by specialist. All of 
these intervals point to critical stages in cancer care, including patient awareness of 
symptoms, access to family doctors, capacity of specialists to handle demands, and 
so on.   
The literature suggests that one of the most important delays is the time from 
  
111 
first symptoms until first visit to a general practitioner (Moody et al., 2004). 
Regrettably, this information is not available for the cohort in this study.  
Furthermore, the focus of this study was on the functioning of the pulmonary 
oncology program at the JGH and as such was not concerned with the clinical 
trajectory prior to the first specialist visit. However, this delay remains an important 
area of research, especially considering the dearth of evidence in Canada, and should 
be the subject of a future study.   
A patient’s clinical trajectory does not end at the first treatment.  Once first 
line treatment is completed, it is essential to ensure that patients are followed and 
continue to successfully navigate the health care system. Quality cancer care must be 
maintained from the beginning to the end of a patient’s illness trajectory.  At the 
JGH, a nurse pivot is assigned to each patient to ensure that they have a guide 
through every step of their illness. It must be clear that patients are not abandoned 
once they have completed their first line treatment.  Regular follow-up and referral 
to other specialists and members of the interdisciplinary team must be pursued.  
Examining waiting times and treatment trajectories for patients after they have 
completed their first treatment is an important factor in ensuring quality care.  
Attention must also be paid to other treatments aside from chemotherapy, radiation, 
and surgery.  Services such as psychological consultations, nutrition, physiotherapy, 
pain management, and all other quality-of-life care must also be provided in a timely 
manner.  Determining the waiting time from referral to consultation would assist in 
the assessment of clinical performance for these services. 
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CONCLUSIONS          
The results of the audit of waiting times for the pulmonary oncology service 
at the Jewish General Hospital are promising. Strengths and weaknesses in the 
service have been identified, and steps have already been taken to improve on 
certain aspects of service provision.  This is facilitated to a large degree by a culture 
of continual research, quality assessment, collegiality and communication that exists 
within the pulmonary oncology program.  
The objectives of this study were (1) to audit the performance of the 
interdisciplinary pulmonary oncology service at the Jewish General Hospital with 
respect to waiting times for key intervals and subgroups of patients; (2) to compare 
waiting times in the clinical trajectory of lung cancer patients seen at the Jewish 
General Hospital with existing waiting time guidelines; and (3) to determine those 
factors associated with longer waiting times in this population.  
The audit of clinical performance of the pulmonary oncology service was 
greatly facilitated by the quality of the data that was available. In the continuing 
absence of electronic medical records across hospitals in Canada, the maintenance of 
an electronic patient database provided detailed, thorough, and high-quality data for 
this project.  Maintaining such a database requires substantial financial and human 
resources, but the benefits in terms of ongoing quality assurance monitoring are 
plentiful, as evidenced in this study.   
Comparing the waiting times achieved by the pulmonary oncology service 
against existing benchmarks and recommendations has provided a picture the JGH’s 
performance and the quality of clinical services. In general terms, the pulmonary 
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oncology service is close to achieving, or has achieved, many of the benchmarks set 
out by the various organizations. Weaknesses have been identified, however, 
particularly in the area of radiation therapy.  It is not clear which set of guidelines is 
the most useful, as each have their benefits and drawbacks, but the members of the 
interdisciplinary pulmonary oncology team felt that the recommendations of the 
British Thoracic Society were most pertinent to their practice. 
The factors associated with longer waiting times in the patient population at 
the Jewish General Hospital are consistent with what is seen in the literature.  In 
particular, early stage and better performance status are well-documented predictors 
of waiting times. Waiting times associated with age and treatment modality were not 
as commonly seen in the literature.  The factors predicting longer waiting times in 
the population of lung cancer patients at the JGH have been communicated to the 
interdisciplinary team members and steps are being taken to address the weaknesses.  
In broader terms, Canadians should expect the same standards of timeliness 
irrespective of their province of origin.  Although waiting time benchmarks are the 
purview of the provinces, efforts should be made to ensure that standards are similar 
across Canada, and the indicators used to monitor those standards are comparable. 
Making performance indicators available to the public and reporting on progress is a 
vital step towards harmonization and reduction of waiting times across the country. 
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ANNEX 1: 
 
A. CLINICAL TRAJECTORY OF A TYPICAL 
PATIENT 
B. CLINICAL TRAJECTORY OF A PATIENT 
SEEN BY A THORACIC SURGEON PRIOR TO 
BEING REFERRED TO A PULMONOLOGIST 
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Figure A-1: Clinical trajectory of a typical lung cancer patient 
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Figure A-2: Trajectory of patients seen by a thoracic surgeon prior to being 
referred to a pulmonologist 
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ANNEX 2: 
 
 FURTHER RESULTS 
 
  
V 
RESULTS           
The results presented below complete the analysis of waiting time intervals 
presented in the article Waiting times in the clinical trajectory of patients with lung 
cancer, found in Section 4.  Figure 1 from section 4 is reproduced below as Figure 5, 
with additional intervals identified. 
 
Figure A-3: Clinical intervals in the treatment of lung cancer patients 
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Interval D-ICC: From diagnosis to presentation at interdisciplinary cancer 
conference  
The median time from diagnosis to first presentation at the interdisciplinary 
conference was 13 days (IQR 6-27 days) (n=313).  32 patients were not presented at 
the ICC at any point during their treatment and therefore were excluded from the 
interval analysis. Fifty-three percent of these patients never presented at ICC were 
surgical patients, and ninety-seven percent of patients not presented to ICC were 
diagnosed in 2004 and 2005.  The remainder of patients were excluded for negative 
intervals, that is, they received their diagnosis prior to being presented at the ICC. 
For patients with NSCLC (n=275) the median time was 13 days and for patients with 
SCLC (n=38) the median time was 11.5 days.  
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Interval ICC-DTT: From presentation at interdisciplinary cancer conference to 
decision to treat 
The median time from first presentation at the ICC to decision to treat was 0 
days (IQR 0-10 days) (n=272). Patients receiving supportive care (n=60) were 
excluded from the analysis. The remainder of patients excluded from the analysis 
due to negative intervals were patients who were referred to the pulmonary service 
following surgery, or who were seen in-hospital.  
 
Interval DTT-R: From decision to treat to ready to treat 
Ninety-six percent of patients were ready to treat on the same day as the 
decision to treat. The remaining 4% of patients had delays between their decision-to-
treat date and their ready-to-treat date of 13-293 days. These are due to patient 
factors such as travel (2pts), initially refusing treatment (5pts), clinical deterioration 
(2pts), seeking second opinion before returning for treatment (1pt), or recovery from 
surgery (either a diagnostic thoracotomy or a surgery unrelated to their lung cancer) 
(5pts).  
 
Table A-1 presents the results of the bivariate and multiple logistic regression 
analysis of patient adherence to CCO waiting time guidelines.  In bivariate analyses, 
only age (p<0.001) and first treatment (p=0.048) were significantly correlated with 
adherence to CCO guidelines. In multiple logistic regression analysis, age and first 
treatment were once again significant.  Patients aged 65-75 were 2.2 times less likely 
than patients under 65 to meet CCO guidelines.  Patients over 75 were 2.6 times less 
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likely to meet CCO guidelines.  Patients receiving chemotherapy as their first 
treatment were 3.6 times less likely than patients receiving surgery to meet CCO 
guidelines. Patients receiving radiotherapy as their first treatment were 25 times less 
likely than patients receiving surgery to meet CCO guidelines. 
 
Table 1: Crude and adjusted Odds Ratios of being seen within CCO-
recommended waiting time guidelines 
 
N= 371 ORcrude (95% CI) 
 
ORadjusted (95% CI)  
Age 
<65 
65-75 
>75 
 
1.00* 
0.71 (0.43-1.18) 
0.37 (0.21-0.65) 
 
1.00* 
0.46 (0.25-0.86) 
0.39 (0.19-0.81)  
Stage 
IA-IIIA, LTD 
IIIB-IV, EXT 
 
0.46 (0.29-0.72) 
1.00* 
 
1.3 (0.69-2.50) 
1.00* 
Diagnosis 
SCLC  
NSCLC 
 
 
0.56 (0.26-1.22) 
1.00* 
 
1.72 (0.71-4.16) 
1.00* 
ECOG Performance Status 
0-1 
2-3 
 
0.75 (0.44-1.28) 
1.00* 
 
0.69 (0.36-1.34) 
1.00* 
First consult 
Pulmonary oncology clinic 
Emergency Department 
In-hospital 
 
1.30 (0.73-2.30) 
0.65 (0.24-1.76) 
1.00* 
 
0.62 (0.29-1.30) 
0.46 (0.13-1.63) 
1.00* 
First treatment 
Chemotherapy 
Radiation 
Surgery  
 
 (0.12-
0.56) 
0.04 (0.02-0.10) 
1.00* 
 
0.28 (0.11-0.72) 
0.04 (0.01-0.1) 
1.00* 
 * Reference category 
 
Focus group 
 
 The group suggested that an appropriate waiting time for the interval FC-D is 
30-45 days and that patients at the JGH waited an average of 45 days.  For the 
interval R-FT, the group suggested that an appropriate waiting time was within one 
week for chemotherapy patients, within 10 to 14 days for radiotherapy patients, and 
within 2 weeks for surgery patients.  They estimated that these same times were the 
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average waits for patients at the JGH. The group suggested that an appropriate 
waiting time for the overall interval FC-FT for all patients is six weeks, and they 
estimated that this was the average for patients seen at the JGH.   
When asked about the usefulness of the benchmarks and guidelines of CCO, 
BTS, and radiation therapy, the group concluded that the Cancer Care Ontario 
guidelines were overly general to apply to the lung cancer population, and therefore 
the guidelines were not perceived as particularly useful. The British Thoracic 
Society guidelines, however, were met with support. They were sufficiently specific 
to be useful, and they also reflected achievable targets for the pulmonary oncology 
service. The pan-Canadian guidelines were perceived as too lenient, even in light of 
the demands on the radiation oncology department from other tumor sites.  The 
clinicians felt that a maximum waiting time of ten days to two weeks was ideal for 
both palliative and curative radiotherapy ("Focus group," June 19, 2008).   
 
 
 
